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Autoimmune diseases are the result of a severe immune response targeted against native 
tissues. Current strategies in the clinic to treat autoimmunity involve administering 
immunosuppressant medications which suppress broad components of the immune system. 
While effective for managing symptoms, reduced immune competency leads to harmful side 
effects such as increased risk for infection. Therefore, developing more targeted approaches to 
induce immune tolerance in the treatment of autoimmunity are highly desirable.  
One approach to induce antigen-specific tolerance has been to administer antigen coupled 
to poly(lactide-co-glycolide) (PLG) nanoparticles. These nanoparticles have been effective in 
treating models of autoimmunity, allergy, and transplant rejection, however the mechanism of 
action is poorly understood. Herein contains investigations of downstream cellular and molecular 
events following nanoparticle internalization by antigen-presenting cells (APCs). Increasing the 
amount of both administered nanoparticles and coupled antigen led to higher levels of antigen 
presentation on the APC surface. Co-stimulatory analysis of APCs with detectable MHC-
restricted antigen revealed a significant reduction of positive co-stimulatory molecules (CD86, 
CD80, and CD40) as nanoparticle concentration was increased. These trends in co-stimulatory 
expression were not observed in APCs administered increasing amounts of soluble antigen, 
suggesting the critical role of antigen coupling to nanoparticles.  
Cell signaling activity of APCs treated with either antigen-coupled nanoparticles (PLG-
OVA) or antigen-coupled splenocytes (SP-OVA) were compared to identify tolerance 
mechanisms resulting from different antigen delivery vehicles. Network analysis revealed NF-
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KB had an integral role within macrophages to connect signaling among several different 
transcription factors while NF-KB was less critical to integrate signaling across dendritic cell 
networks.  Macrophages treated PLG-OVA or SP-OVA before co-culture with activated T cells 
did not dramatically affect T cell response. Dendritic cells treated SP-OVA compared to PLG-
OVA were more effective to attenuate not only IL-2Rα expression but also other indicators of T 
cell activity. Inhibiting NF-KB signaling in macrophages treated with SP-OVA led to reduced T 
cell expression of IL-2Rα, suggesting a potential role for targeting NF-KB activity to improve 
tolerance induction. 
Nanoparticles encapsulating small interfering RNA (siRNA) were investigated to inhibit 
autoimmune signaling pathways. A feasibility study was conducted focusing on CCR2, a 
chemokine receptor correlated with worse prognoses in models of multiple sclerosis. An siRNA 
mixture targeting CCR2 expression (siCCR2) was complexed to polyethylenimine prior to PLG 
encapsulation. Complexed and encapsulated siCCR2 were evaluated by measuring CCR2 levels 
and cell migratory potential. Encapsulated siCCR2 were also examined by administering 1.0 mg 
in a mouse model of multiple sclerosis on Days 7, 9, and 11 following disease induction. Mean 
clinical scores were significantly reduced compared to administering either encapsulated non-
specific siRNA complexes or buffered solution. These findings suggest encapsulated siRNA 
complexes may have clinical applications for the treatment of multiple sclerosis and other 
autoimmune diseases.  
This work identified several mechanisms, including IL-10 production, T cell apoptosis, and 
reduced T cell proliferation affected by antigen-coupled nanoparticle treatment. Intracellular 
signaling activity of treated APCs revealed a central role of NF-KB to mediate macrophage 
signaling. Macrophages treated with SP-OVA and an NF-KB inhibitor prior to co-culture with 
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activated T cells resulted in attenuated T cell activity. More targeted approaches to inhibit 
molecules of interest were explored using PLG nanoparticles encapsulating siRNA. Initial 
studies focused on CCR2, whose expression during autoimmunity is correlated with worsening 
prognosis. Encapsulated CCR2-targeting siRNA had good feasibility for reducing both in vitro 









Chapter 1: Introduction 
1.1 Motivation 
Autoimmune diseases represent a severe worldwide health burden. There are currently 81 
identified autoimmune diseases, affecting approximately 4.5% of the world’s population. [1] 
Many autoimmune diseases are chronic in nature, leading to a reduced life expectancy as well as 
a diminished quality of life. [2] Typical therapeutic strategies for autoimmune diseases focus on 
systemic immune suppression. However, the harmful side effects of disrupting immune 
competency motivates the development of antigen-specific interventions. These approaches 
would specifically target autoimmune pathways for inactivation while preserving the remainder 
of the immune system to prevent opportunistic infections. 
Antigen-specific approaches to desensitize the immune system have been used for nearly a 
century, primarily to treat allergies by administering a gradually increasing dose of allergen over 
an extended period of time. This type of approach has shown promise to also treat models of 
autoimmune disease through the administration of escalating doses of autoantigen. [3] However, 
the difficulty with controlling dose escalation, length of treatment window, and risk for 
anaphylaxis has limited widespread adoption of these hyposensitization therapies. Interestingly, 
instead of soluble administration of autoantigen, attaching the autoantigen to nanoparticles prior 
to administration has led to rapid and long-lived antigen-specific tolerance. [4] The use of 
nanoparticles to treat autoimmune diseases holds potential for clinical translation, but a better 
understanding of the cellular and molecular mechanisms would help ensure safety and efficacy.  
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Nanoparticles are not the exclusive antigen delivery vehicle to induce antigen-specific 
tolerance. In fact, attaching autoantigen to donor cells has been previously demonstrated to also 
induce antigen-specific tolerance. [5] The use of cell-based vehicles is a logical  platform, as the 
immune system routinely removes apoptotic cells from circulation without triggering an immune 
response. Interestingly, the chemical treatment used to attach autoantigens to donor cells results 
in apoptosis, [6] thus it is highly probable that administering antigen attached to donor cells 
triggers endogenous signaling pathways that overlap with apoptotic cell clearance. A comparison 
of the signaling pathways used by antigen-coupled nanoparticles and antigen-coupled cells 
would therefore provide interesting insights to identify additional signaling molecules whose 
activity could be modulated to enhance the tolerance induction efficiency of nanoparticle-based 
antigen-specific therapy. Antigen-coupled nanoparticles offer several advantages in the 
therapeutic setting compared to antigen-coupled cells, which include ease of manufacturing and 
storage. 
Concern over an anaphylactic reaction will undoubtedly overshadow any antigen-specific 
approaches that reintroduce antigen into a sensitized patient. Studies of the cellular and 
molecular mechanisms contributing to autoimmunity have identified several pathways that may 
be targeted directly to reduce the occurrence of autoimmunity. [7] The use of siRNA molecules 
represent an effective approach to target these signaling pathways and suppress an unwanted 
immune response. The research that follows seeks to better understand how existing antigen-
specific therapies work, with the goal of improving the safety and efficacy of these therapies to 





This dissertation focuses on engineering strategies that leverage polymer nanoparticles to 
modulate the immune response towards tolerance. The following chapters provide background 
information, experimental methodology, results, conclusions, and future directions of the 
different strategies explored in this work. Chapters 2 and 3 contain relevant background 
information with regard to the immune system and biomaterials, respectively. Chapters 4 through 
6 describe the completed experimental work. Chapter 7 discusses the conclusions and potential 
future directions revealed by the investigations herein. 
Chapter 2 presents an overview of the immune system with particular focus on the steps to 
activate an immune response. Different hypotheses are explored with regard to the initiation of 
autoimmunity, followed by an evaluation of various antigen-specific treatments previously 
explored in research. Chapter 3 introduces biomaterials, particularly emphasizing a synthetic 
polymer, poly(lactic-co-glycolic acid), already used in several FDA approved drugs and medical 
devices. This chapter focuses on uses of this material at the nanoscale to deliver therapeutic 
molecules to effect disease prognosis. 
Chapter 4 closely examines tolerance mechanisms triggered by treatment with antigen-
conjugated nanoparticles. This investigation particularly emphasized the variables of 
nanoparticle dose and conjugation levels of antigen. Nanoparticle efficacy for tolerance 
induction was first demonstrated in vivo with a mouse model of multiple sclerosis administered 
different doses of nanoparticles with different levels of antigen conjugation. Several in vitro 
studies then examined cell signaling activities following nanoparticle internalization by antigen-
presenting cells and the efficiency of antigen processing and presentation. T cells which mediate 
autoimmunity in this disease model were isolated and co-cultured with innate immune cells 
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administered nanoparticles to identify the specific antigen-specific tolerance mechanisms at 
work. 
Chapter 5 focuses on the role of the antigen delivery vehicle for tolerance induction. 
Nanoparticle-mediated and cell-mediated delivery of antigen is compared with regard to 
activating effector T cell responses. Cell signaling pathways were inferred and constructed based 
on the signaling activities of innate immune cells following internalization and presentation of 
antigen. A small molecule inhibitor was used to reduce the activity of an important signaling 
molecule to validate the network and attempt to replicate tolerance mechanisms triggered by 
cell-mediated antigen delivery with nanoparticle-mediated antigen delivery. 
Chapter 6 explores loading a bioactive molecule, siRNA, into the nanoparticle formulation 
to disrupt key chemokine signaling that regulates inflammatory cell migration. Several in vitro 
studies examine the intracellular nanoparticle localization, chemokine signaling, and cell 
migration. These nanoparticles are then used in vivo to test for ameliorated disease symptoms in 
a mouse model of multiple sclerosis. 
Chapter 7 draws conclusions from the research studies conducted in this work and provides 









Chapter 2: The Immune System: Autoimmunity and Tolerance 
2.1 The Human Immune System 
A healthy human immune system functions to protect the body from harmful infection by 
pathogens. Cells comprising the immune system are found throughout the body, allowing for a 
quick response to pathogenic invasions that may occur at any time or place. Immune cells 
circulate throughout the body using both blood vessels of the cardiovascular system as well as 
lymphatic vessels of the lymphatic system. [8] Blood and lymphatic vessels connect through the 
spleen and lymph nodes, respectively, which serve as important locations for coordinating 
immune cell activity and the immune response. [9] 
2.1.1 Innate and Adaptive Immunity 
The immune system is quite complex, but is often organized into two major components: 
innate and adaptive immunity. When a pathogen breaches the body’s surface barriers, it is 
typically met first by components of  innate immunity. Innate immunity responds immediately 
with non-specific mechanisms to attempt to resolve the invasion. [10] The cell-mediated 
mechanisms of the innate response consist primarily of phagocytosis, the internalization of 
extracellular material that binds receptor molecules located on the phagocytic cell’s surface. [11] 
Innate immunity also consists of a humoral-mediated mechanism that includes complement 
proteins and antibodies which opsonize or decorate the surface of pathogens to increase their 
likelihood of phagocytosis. [12] 
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A small number of cell types are capable of phagocytosis, including macrophages, 
dendritic cells, monocytes, and neutrophils. Phagocytosis internalizes extracellular material into 
the cell via membrane-bound cellular compartments called endosomes, or more specifically, 
phagosomes, the endosomes resulting specifically from phagocytosis. [11] As phagosomes are 
shuttled further inside the cell along the endocytic pathway, the compartmental pH decreases as 
enzymes are introduced and become activated to break down contents of the phagosome. [13] At 
the end of the pathway, phagosomes fuse with lysosomes that contain a variety of different 
hydrolytic enzymes to thoroughly degrade remaining materials within the phagosome.  
The degradation process generates small molecular fragments, or antigens that are loaded 
onto major histocompatibility complex (MHC) molecules for antigen presentation at the cell 
surface. There are two classes of MHC molecules, including class I (MHC-I) and class II (MHC-
II) molecules. MHC-I are expressed by most cell types in the body and typically associate with 
antigens from proteins synthesized by the cell. In contrast, MHC-II expression is primarily 
limited to phagocytic cells, such as macrophages and dendritic cells, also referred to as antigen-
presenting cells (APCs). [14] MHC-II typically associate with antigens from proteins 
internalized from the extracellular space. Surface availability of MHC-restricted antigen is 
critical for signaling to T cells to induce adaptive immune responses. 
Adaptive immunity is comprised of T cell and B cell responses that are highly efficient for 
pathogen elimination due to their antigen-specificity. Different T cell subsets preferentially 
interact with either MHC-I or MHC-II depending on surface expression of CD8 or CD4, 
respectively. [15] CD4+ T cells are typically associated with providing helper functions while 
CD8+ T cells predominantly possess a cytotoxic-suppressor phenotype. [16] CD4+ T cells help 
activate B cells to produce antibodies which tag pathogens using antigen specificity to facilitate 
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their elimination. CD8+ T cells induce cell death when cells present the specific MHC-restricted 
antigen.  
There are two main signals provided by APCs necessary for effective CD4+ and CD8+ T 
cell activation. The first signal consists of MHC-restricted antigen. [17] Not all T cells can detect 
the MHC-restricted antigen on the APC surface. Initially, only a small number of T cells in the 
body express the specific T cell receptor necessary to detect a particular MHC-restricted antigen.  
However, upon binding its cognate antigen through the T cell receptor, T cells can rapidly 
proliferate to create a substantial population to detect and respond to the specific antigen. 
Alternatively, T cells may also enter a state of inactivity, or anergy, when their T cell receptors 
are engaged. [18] The T cell fate depends heavily on the presence or absence of a second signal 
from APCs, co-stimulatory molecules. 
Interactions between co-stimulatory molecules on the APC surface and receptors on the T 
cell surface are critical for an effective immune response. [19] Among the most well-known 
interactions are those between CD80 and CD86 on the APC surface with CD28 on the T cell 
surface. In addition, CD40 interactions with T cells can help mature APCs to elicit stronger 
effector T cell responses. Without these co-stimulatory molecules, engagement of the T cell 
receptor complex can result in deletion or anergy of the T cell. APCs may also express negative 
co-stimulatory molecules, such as PD-L1, which play a major role in immune tolerance. [20] 
Both macrophages and dendritic cells are capable of activating T cells, although each cell 
type makes contributions to different aspects of the activation process. Dendritic cells have a 
higher surface density of MHC-II compared to macrophages, and thus provide more of the cell-
cell input signals necessary to activate CD4+ T cells. [21] Macrophages can adopt different 
phenotypes depending on whether they received classical activation or alternative activation 
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signals. The phenotype influences the signaling mediators that macrophages produce, which can 
either be pro-inflammatory and facilitate T cell activation or anti-inflammatory and suppress T 
cell activation. [22] 
2.1.2 Intercellular and Intracellular Immune Signaling 
Many of the immune processes mentioned above are directed and regulated by receptor-
mediated signaling. Extracellular cues are first detected by cell surface receptors, which trigger a 
cascade of intracellular signaling activity that results in changes to cell behavior which may 
include increased production of signaling molecules to engage additional cells in a coordinated 
response. For example, the immune response is first initiated upon detection of extracellular 
molecules known as pathogen-associated molecular patterns (PAMPs), structures typically found 
only in bacteria or viruses. Most phagocytic cell types possess toll-like receptors (TLRs) which 
bind PAMPs, an event that triggers the propagation of signal transduction pathways leading to 
upregulated surface expression of co-stimulatory molecules, trafficking to the spleen or lymph 
nodes, and secretion of chemical mediators to promote inflammation. [23] 
Cytokines are important intercellular chemical mediators, synthesized and secreted by cells 
to influence the behavior of their surrounding cells. Many cell types ranging from macrophages 
to T cells are capable of producing cytokines. While these cells may produce related cytokines to 
amplify a particular immune response, one cell type’s cytokines may also work to inhibit the 
actions of other cytokines already present in the environment. [24] Cytokines can include 
interleukins (IL), such as IL-2 and IL-4, which promote proliferation and differentiation of T 
cells, respectively. Another class of cytokines is the interferons (IFN), such as IFN-γ, which 
activates macrophages, and along with IL-1 and IL-12, work to promote inflammation. One other 
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important cytokine group is the chemokines, such as CCL2, which drives inflammation by 
inducing cell chemotaxis.  
Transcription factors (TFs) play an important role in the intracellular signaling that 
converts extracellular cues into the appropriate cell behavioral changes. TFs bind to gene 
promoter regions in the cell nucleus and recruit cellular machinery needed to initiate gene 
expression. TFs can be categorized by the specific DNA sequence that they bind to, and over 
1,000 different TFs have been identified in humans. [25] TFs can also be characterized by 
signaling pathways they are involved with. Several TFs have been identified in TLR signaling 
pathways, including NF-KB and AP-1. The STAT family has also been identified in the IFN 
signaling response. 
RNA interference represents a sequence-specific approach for controlling gene expression. 
Several molecules are capable of mediating RNA interference, one of which is short interfering 
RNA (siRNA). Molecules of siRNA are first formed when Dicer enzyme cleaves long double-
stranded RNA or small hairpin RNAs into siRNA, which are approximately 21 to 24 base pairs 
in length. [26] When siRNA is in the cytosol, it can associate with RNA-induced silencing 
complex (RISC) and possibly other factors which then scan mRNA transcripts for sequence 
complementarity. When complementary mRNA sequence is detected, the RISC complex 
degrades the mRNA to prevent its further translation into protein and thereby inhibit gene 
expression. The use of siRNA to downregulate transcription factor activity has been 
demonstrated to attenuate cancer growth. [27] 
2.2 Autoimmune Diseases 
The immune system contains regulatory mechanisms to ensure its response is directed only 
toward pathogens, but at times, the immune system can still mistakenly attack the body’s own 
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molecules. This undesirable response often leads to an autoimmune disease. There are over 80 
identified autoimmune diseases which affect an estimated 23.5 million Americans. [28] Diseases 
manifest with markedly different symptoms, ranging from impaired motor function in multiple 
sclerosis to hypoglycemia in Type 1 diabetes, but all share the common underlying physiology of 
an immune response directed against molecules normally found in the body.  
2.2.1 Central and Peripheral Tolerance 
To limit the occurrence of autoimmunity, central tolerance is used by the immune system to 
remove self-reactive T cells from circulation. These self-preservation processes occur in the 
thymus once T cell precursors undergo genetic recombination to form their T cell receptor. [29] 
Many variations of the T cell receptor may result from recombination, producing cell populations 
with a variety of different receptors able to bind a wide range of antigens. Inevitably, 
recombination also produces self-reactive T cells able to cause autoimmunity, and so subsequent 
T cell maturation includes a two-step selection process. First, positive selection identifies T cells 
able to bind MHC molecules. Those that fail positive selection do not survive, ensuring that T 
cells respond only to antigen that is MHC-restricted. Next, negative selection is used to remove 
self-reactive T cells. Within the thymus, T cells are introduced to MHC molecules loaded with 
several different self antigens. T cells that bind any of these antigens with high affinity will 
undergo apoptosis. [29] While positive and negative selection reduce the likelihood of 
developing autoimmunity, they do not eliminate all self-reactive T cells from entering 
circulation, requiring additional tolerance mechanisms to suppress their activity in the periphery. 
Peripheral tolerance describes mechanisms for suppressing the activity of self-reactive T 
cells already in circulation. One mechanism is the stringent activation threshold for T cells. 
Circulating self-reactive T cells must still encounter both MHC-restricted antigen and co-
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stimulatory molecules on the surface of antigen-presenting cells in order to become activated. 
Without an infection, antigen-presenting cells are unlikely to encounter the PAMPs which trigger 
expression of co-stimulatory molecules. [30] Self-reactive T cells that receive only the antigen 
signal alone will adopt a non-responsive state of anergy. [31] Other mechanisms to suppress self-
reactive T cells include production of immunosuppressive cytokines, such as IL-10 and TGF-β. 
[32] These cytokines are typically secreted by regulatory T cells, which are T cells that possess 
receptors for self antigens. But instead of producing an autoimmune response when their cognate 
antigen is detected, activated regulatory T cells work to suppress the immune response. 
Certain tissues and organs maintain an environment biased towards immune tolerance. 
These regions of the body are often referred to as immune privileged sites, where foreign antigen 
can be introduced without provoking an immune response. Among these sites include the brain, 
eyes, and placenta. [33, 34] Tolerance is maintained through a combination of reduced entry for 
immune cells, low expression of MHC molecules, and continuous production of 
immunosuppressive cytokines.  
2.2.2 Possible Causes of Autoimmune Diseases 
While the causes of autoimmune diseases are not precisely known, several factors, 
including both genetic predisposition and environmental exposures have been implicated. 
Molecular mimicry describes one possible hypothesis that there exists a potential cross-reactivity 
between native and pathogenic antigens. [35] Certain pathogens are believed to possess antigens 
with a similar peptide sequence or structure to those found on human cells. When invaded by 
these pathogens, the immune system cannot distinguish the difference and will attack both 
sources of antigen, resulting in autoimmunity. In this case, a patient who develops an 
autoimmune disease due to molecular mimicry had both a genetic predisposition, with the 
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preexistence of a potentially cross-reactive antigen, as well as environmental exposure to the 
pathogen.  
Epitope spreading is another hypothesis to describe the initiation of autoimmunity. When 
activated T cells migrate to the infection site, they destroy infected cells and release cytokines to 
remodel the local environment. In the process, cells in the vicinity may also suffer damage, 
releasing their own peptides that become internalized by phagocytes. [36] Although phagocytes 
routinely display native antigens loaded onto MHC molecules at the cell surface, when 
pathogens are present, these phagocytes will also express co-stimulatory molecules which 
provide the necessary signals to activate self-reactive T cells.  
2.2.3 Current Treatments of Autoimmune Diseases 
Autoimmune diseases are chronic conditions that lack cures, and any prescribed treatments 
primarily serve to manage the disease symptoms. The mechanism of action used by these 
treatments is typically broad and non-specific, resulting in suppression of large components of 
the immune system. [37] For example, corticosteroids are a powerful immunosuppressant which 
are administered in situations that include autoimmunity, allergy, and organ transplants. 
However, these types of drugs compromise the patient’s immune system, often resulting in 
unfortunate side-effects, which can include increased susceptibility to opportunistic infections. 
[38] 
The development of antigen-specific therapeutic strategies would be a major improvement 
in the treatment of autoimmune diseases. This type of approach would focus action on self-
reactive T cells and the related immune components that directly contribute to autoimmunity. 
Although not all autoimmune diseases have a well-defined self antigen implicated for causing 
autoimmunity, multiple sclerosis is one disease where several myelin peptides have been 
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identified as the antigens. [39] Treatments currently prescribed to patients with multiple sclerosis 
include IFN-β and glatiramer acetate. IFN-β works non-specifically by inhibiting expression of 
MHC class II molecules, IL-12 production, and T cell proliferation. [40] On the other hand, 
glatiramer acetate is a polymer of four amino acids found in myelin. Delivered subcutaneously, 
this treatment is believed to activate regulatory T cells which help suppress the autoimmune 
response. [41] Studies comparing the two treatment courses have not found much difference in 
disease prognosis. [42] However, the targeted approach of glatiramer acetate may be more 
effective to reduce undesirable side-effects of broad immune suppression. 
The efficacy of novel therapeutic approaches to treat autoimmunity are often tested using a 
disease model, called experimental autoimmune encephalomyelitis (EAE). EAE is a mouse 
model of human multiple sclerosis. Disease is established in mice by inducing an immune 
response against myelin antigen. [43] The immune response leads to activation and proliferation 
of myelin-reactive CD4+ T cells which enter the central nervous system and promote 
inflammation. [44] Massive infiltration of inflammatory cells results in tissue injury and 
paralysis.  
Antigen-specific approaches to treat autoimmunity often incorporate the antigen targeted 
by self-reactive T cells into the therapeutic formulation. [45] There remain safety concerns 
surrounding the reintroduction of antigen to a patient with autoimmunity, as the immune system 
is already sensitized to the antigen which could potentially trigger anaphylaxis. However, one 
effective strategy has been to load the self antigen onto apoptotic cells using a chemical cross-
linker, such as ethyl carbodiimide. [46, 47] Administering the antigen-conjugated apoptotic cell 
intravenously results in upregulated anti-inflammatory cytokines, negative co-stimulatory 
molecules, and the activity of T regulatory cells. [48] Human clinical trials have shown good 
14 
 
safety indications with this approach, first collecting the patient’s own cells and loading with 
several myelin peptides before intravenously administering the modified cells back into the 
patient. [49] One major improvement being explored for this approach has been to use an off-
the-shelf product for antigen coupling, which would eliminate the expensive and complicated 
step of removing cells from the patients. [50] Strategies from biomaterial engineering, such as 
loading antigen onto synthetic particles instead of the patient’s cells may improve the ease of 











Chapter 3: Biomaterial Strategies for Immune Modulation 
3.1 Advances in Biomaterials and Drug Delivery 
A biomaterial describes any material used in the construction of medical devices. Natural 
materials, such as wood and metal, have functioned as biomaterials throughout history, often to 
replace appendages lost to disease or trauma. More recently, synthetic materials such as alloys, 
composites, and polymers have become the biomaterials of choice. [51] These advanced 
materials offer improved functionality, enabling the development of new applications, especially 
those occurring within the body.  
One application benefitting from advancements in biomaterials is drug delivery. [52] In 
drug delivery, biomaterials are infused with pharmaceutical products for controlled release inside 
the body. Initial drug delivery formulations were developed as once-a-day tablets, which could 
be taken orally and used to treat chronic conditions. [53] However, larger drug molecules, such 
as peptides or proteins were not suitable for oral delivery, and thus required a more advanced 
delivery system. [54] In the 1980s, drug manufacturers found an innovative solution by 
encapsulating peptide within injectable microparticles made of a biodegradable and 
biocompatible polymer. [55] This major achievement brought widespread attention to particle-
based drug delivery systems which continue to be an actively researched technology area within 
this field. 
Over the past several years, the field of drug delivery has increasingly focused on 
improving the targeting of therapeutic delivery. The primary goal is to deliver therapeutic 
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interventions to regions of the body that require treatment, while minimizing off target effects 
and toxicity. Developing particles on the nanoscale has been shown to provide a certain level of 
specificity for nanoparticle accumulation in particular regions and cell types of the body. [56] 
Continued advances in the research of nanoparticle-based therapeutics has resulted in many 
experimental therapies currently under clinical study. [57] 
3.2 Poly(lactic-co-glycolic acid) Nanoparticles 
Synthetic polymers, including poly(lactic acid), poly(glycolic acid), poly(ethylene glycol), 
and their copolymers, are commonly used in the design of nanoparticle therapeutics. [58] One 
copolymer which has been successfully used in several commercially available drugs is 
poly(lactide-co-glycolide), or PLG. When introduced with water, PLG undergoes hydrolytic 
degradation, causing the copolymer to break down into its constituent monomers that are 
naturally found in the body. [59] The good biodegradable and biocompatible properties of PLG 
were likely major factors leading the Food & Drug Administration to approve PLG products for 
medical use in humans. [59] As such, experimental medical devices or drugs that incorporate 
PLG into their design may be at an advantage when seeking future regulatory approval. 
3.2.1 Fabrication 
The classical approach to fabricating PLG nanoparticles is the emulsification solvent 
evaporation technique. The process begins by dissolving polymer in organic solvent and then 
creating an emulsion by the addition of water and a surfactant. Sonication or homogenization of 
this mixture generates droplets that give rise to nanoparticles when the solvent within each 
droplet traverses the aqueous phase and evaporates at the emulsion-air interface. [60] This 
fabrication technique is often specified as single emulsion, which can produce nanoparticles that 
encapsulate hydrophobic molecules dissolved in the initial polymer solution. A variation of this 
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technique, called double emulsion, is preferable to generate nanoparticles that encapsulate 
hydrophilic molecules. [61] In the double emulsion procedure, an initial emulsion is formed with 
polymer and an aqueous solution containing dissolved hydrophilic molecules. Following 
sonication or homogenization, water and a surfactant are added to create a secondary emulsion 
and the mixture is sonicated or homogenized once more to create the final droplets that give rise 
to nanoparticles.  
Other approaches to fabricate PLG nanoparticles include nanoprecipitation and spray-
drying. Nanoprecipitation, or interfacial deposition, involves dissolving polymer and drug in 
organic solvent which is then added dropwise to water. [62] The resulting nanoparticles are then 
collected after solvent evaporation. One improvement nanoprecipitation offers over emulsion 
methods is the ability to produce nanoparticles without the use of surfactants which can affect 
biological activities and contribute to toxicity. However, nanoprecipitation is limited primarily to 
entrapping hydrophobic molecules. Spray drying is another fabrication technique, using hot gas 
to rapidly dry a liquid to form solid nanoparticles. While this approach can result in good 
encapsulation efficiencies of hydrophilic molecules, it has been reported to suffer from burst 
release, or a quick initial release of the entrapped payload, compared to a sustained release of 
hydrophilic molecules provided by nanoparticles made by emulsification solvent evaporation 
techniques. [63] 
3.2.2 Degradation 
The copolymer composition can be adjusted in several ways to influence the PLG 
degradation rate and accommodate various biomedical applications. In general, increasing the 
glycolic acid content and decreasing molecular weight have been reported to accelerate PLG 
degradation and thereby drug release. However, glycolic acid content higher than a 50:50 ratio 
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with lactic acid is typically not used due to the reduced solubility during synthesis and uneven 
molecular weight distributions that result. [64] One study of tetanus toxoid release from 
microspheres compared PLG containing a 50:50 monomer ratio alongside PLA containing a 
100:0 ratio of lactic acid to glycolic acid. [65] At 3,000 Daltons, PLG 50:50 had released about 
69% of the encapsulated payload after 30 days while PLA had only released about 28% in the 
same time frame. Increasing molecular weight to 100,000 Daltons, the PLG 50:50 released about 
32% of the encapsulated payload after 30 days while PLA had released about 16% in the same 
time frame. These trends show the potential large contributions of molecular weight and 
monomer ratio for determining degradation rate.  
Other factors reported to affect PLG degradation include environmental acidity and end 
group modification. [66] Studies have correlated lower pH environments with faster PLG 
degradation compared to neutral pH environments. After 16 weeks, PLG macroporous foams 
placed in acidic pH 5.0 began degrading at a faster rate than foams placed at either physiological 
pH 7.4 or intermediate pH 6.4. After 30 weeks, the foams at pH 6.5 and 7.4 had lost 30% of their 
initial mass, whereas foams at pH 5.0 had lost 90% of their initial mass. [67] Environmental pH 
governs the morphological changes to PLG, which may help to explain differences in the 
degradation rate. Degradation results in acidification of the PLG microsphere core, causing 
surface erosion and channel formation at physiological environments. [68] In contrast, an acidic 
environment has a pH balance with the PLG core, preserving the smooth microsphere structure 
during degradation, although it is hypothesized that monomer accumulation within microspheres 
resulting from insolubility at low pH leads to microsphere brittleness and fracturing. Neutralizing 
or capping the carboxylic acid chain ends of PLG with esters helps to extend their half-life. 
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When left free, polymer end chains induce autocatalysis of PLG hydrolysis to accelerate 
degradation.  
3.2.3 Toxicity 
PLG nanoparticles have good biodegradable and biocompatible properties, and 
investigations of their toxicity have largely concluded their safety for internal human use. 
Grabowski et al. [69] examined PLG nanoparticles measuring between 200 to 300 nm, fabricated 
with different surfactants to achieve either neutral, positively, or negatively charged 
nanoparticles. The cytotoxicity of A549 human lung epithelial cells was measured through 
mitochondrial activity and membrane integrity, which revealed good viability in response to 
PLG nanoparticles, especially compared to treatment with inorganic nanoparticles composed of 
titanium dioxide. In a separate study, Tulinska et al. [70] administered PLG nanoparticles to 
human peripheral blood cells and measured for changes in immune cell behavior indicative of 
allergy or toxicity. The studies showed PLG nanoparticles attenuated immune activity, as T cell 
proliferation was reduced following CD3 stimulation and lytic activity of natural killer cells 
decreased in the presence of tumor cells. While the reduced immune activity following 
nanoparticle treatment was concluded to be nanoparticle toxicity, the high cell viabilities would 
suggest rather that interactions between the immune system and PLG nanoparticles are favorable 
for applications in immune modulation. 
3.3 Nanoparticles and Immune Modulation 
The sub-micron size of nanoparticles enables deep tissue penetration and high rates of 
intracellular uptake. Further tuning of size can direct nanoparticles to accumulate in particular 
tissues and cells to either enhance or inhibit the immune response. [56] Additional control over 
interactions with the immune system can be achieved by loading nanoparticles with bioactive 
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molecules, such as adjuvants to stimulate an immune response or corticosteroids to suppress an 
immune response. [71] Controlling the immune response following nanoparticle administration 
is important to ensure their successful therapeutic function.   
3.3.1 Nanoparticle Localization 
Controlling the size of nanoparticles during the fabrication process can predictably 
influence their internal distribution following in vivo administration. One approach to adjust the 
size of nanoparticles made from emulsification solvent evaporation is to vary surfactant 
concentration. Increasing the concentration of poly(vinyl alcohol) from 0.5% (w/v) to 5.0% 
(w/v) helped stabilize smaller emulsion droplets, decreasing the mean particle size from 522 nm 
to 380 nm. [72] Similarly, the average volume of spheroids decreased from 1,000 μm3 to 160 
μm3 as surfactant concentration increased from 1% (w/v) to 4% (w/v). [73] The higher surfactant 
concentration was reported to increase aqueous phase viscosity, producing greater shear forces to 
break down droplets into smaller structures.  
Nanoparticle size plays a major role in their localization within the body. Size-dependent 
nanoparticle accumulation in tissues was determined by HPLC quantification 4 h following 
intravenous administration of polystyrene nanoparticles of varying sizes. [74] As size increased, 
the percent of total nanoparticle retention also increased, most dramatically in the liver, lungs, 
and spleen, compared to the blood, brain, and heart. Nanoparticles smaller than 100 nm more 
easily permeated the vasculature into the renal system and also into peripheral tissues such as the 
skin, muscle, and fat. In a separate study, tissues were analyzed using gel permeation 
chromatography following intravenous administration of 200 and 500 nm PLG nanoparticles. 
[75] Nanoparticle accumulation occurred primarily in the liver, spleen, and lungs, relative to the 
blood, brain, heart, kidneys, and stomach.  
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Route of administration may also play an important role to influence nanoparticle 
localization and disease outcome. Subcutaneous injection of PLG nanoparticles with an average 
size of approximately 200 nm were strongly detected in the brain, heart, kidneys, and lungs, and 
to a lesser extent, the liver, spleen, and lymph nodes. [76] This study was conducted in the 
context of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple 
sclerosis. Consistent abrogation of EAE disease was seen only when both disease-relevant 
myelin antigen and IL-10 were co-delivered in the PLG nanoparticles. Researchers have also 
attempted to establish EAE using dendritic cells pulsed with myelin antigen co-administered 
with pertussis toxin. [77] After three subcutaneous injections of dendritic cells and pertussis 
toxin over a period of 4 weeks, mice displayed mild EAE symptoms. However, mice receiving 
the same dosing regimen through intravenous or intraperitoneal injections did not develop 
symptoms. These studies suggest the reduced efficacy of establishing tolerance via the 
subcutaneous route, especially compared to intravenous or intraperitoneal administration. 
3.3.2 Post-Internalization Cell Response 
The tissues in which intravenously administered nanoparticles accumulate contain an 
abundance of immune cells, such as macrophages and dendritic cells. These cells are quick to 
internalize nanoparticles and reshape the local immune environment. Macrophages efficiently 
internalized PLG nanoparticles with approximate diameter of 389 nm compared to 
microparticles with approximate dimeter of 6.5 μm. [78] The secretion of IL-1β and TNF-α were 
significantly lower in nanoparticle-treated compared to microparticle-treated macrophages, and 
nuclear translocation of NF-KB was also significantly reduced. Dendritic cells were able to 
internalize PLG nanoparticles with average diameter of 280 nm resulting in little effect on the 
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expression of CD40, CD86, or MHC-II molecules. [79] These observations of cell behavior 
following internalization suggest the nanoparticle vehicle is relatively inert. 
Incorporating bioactive molecules into the nanoparticles can further modulate the immune 
response. While molecules activating the immune system are not explored in the work that 
follows, a class of molecules called, toll-like receptor agonists have previously been loaded into 
PLG nanoparticles to stimulate immune responses in applications such as vaccines. [80] But 
rather, we focus here on immune suppressing molecules, such as IL-10 and rapamycin. It was 
previously mentioned that IL-10 encapsulation with antigen delivery resulted in better abrogation 
of EAE. [76] It has also been demonstrated that the presence of rapamycin further suppresses the 
immune response and abrogates EAE clinical score. [79, 81] Oligonucleotides, such as siRNA, 
have also shown therapeutic potential when encapsulated and delivered within nanoparticles for 
immune suppression. [82] These aforementioned studies reporting immune suppression or 
tolerance induction mediated by PLG nanoparticles are of great interest for further investigation 
with regards to immune mechanisms and nanoparticle formulations to provide better targeting 
and specificity over current approaches to treat autoimmune diseases.  
The following chapters discuss research studies that examined and engineered the 
mechanisms of action used by antigen-coupled nanoparticles for immune tolerance. Antigen-
coupled PLG nanoparticles have been effective for reducing the occurrence of EAE symptoms 
which are mediated by CD4+ T cells. Thus, assays were conducted to determine the impact of 
nanoparticle treatment on the CD4+ T cell response. Dynamic measurement of intracellular 
signaling activity following APC internalization of antigen-coupled PLG nanoparticles were 
compared to intracellular signaling activity following APC internalization of antigen-coupled 
cells. Similarities in intracellular signaling activity suggested a common mechanism between 
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nanoparticle processing and cell clearance. Differences in intracellular signaling activity would 
suggest possible signaling molecules to inhibit during nanoparticle treatment to better mimic cell 
clearance responses which suppress immune activity. The feasibility of encapsulating inhibitory 
molecules within PLG nanoparticles was explored using CCR2-targeting siRNA. These loaded 
nanoparticles were administered in vitro and in vivo to evaluate their inhibitory effects on 












Chapter 4: Peptide-Conjugated Nanoparticles Reduce Positive Co-Stimulatory Expression and T 
Cell Activity to Induce Tolerance 
4.1 Abstract 
Targeted approaches to treat autoimmune diseases would improve upon current therapies 
that broadly suppress the immune system and lead to detrimental side-effects. Antigen-specific 
tolerance was induced using poly(lactide-co-glycolide) nanoparticles conjugated with disease-
relevant antigen to treat a model of multiple sclerosis. Increasing the nanoparticle dose and 
amount of conjugated antigen both resulted in more durable immune tolerance. To identify active 
tolerance mechanisms, we investigated downstream cellular and molecular events following 
nanoparticle internalization by antigen-presenting cells. The initial cell response to nanoparticles 
indicated suppression of inflammatory signaling pathways. Direct and functional measurement 
of surface MHC-restricted antigen showed positive correlation with both increasing particle dose 
from 1 to 100 μg/mL and increasing peptide conjugation by two-fold. Co-stimulatory analysis of 
cells expressing MHC-restricted antigen revealed most significant decreases in positive co-
stimulatory molecules (CD86, CD80, and CD40) following high doses of nanoparticles with 
higher peptide conjugation while expression of a negative co-stimulatory molecule (PD-L1) 
remained high. T cells isolated from mice immunized against myelin proteolipid protein (PLP139-
151) were co-cultured with antigen-presenting cells administered PLP139-151-conjugated 
nanoparticles, which resulted in reduced T cell proliferation, increased T cell apoptosis, and a 
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stronger anti-inflammatory response. These findings indicate several potential mechanisms used 
by peptide-conjugated nanoparticles to induce antigen-specific tolerance. 
4.2 Introduction 
Aberrant T cell recognition of host antigen can trigger an immune response resulting in 
autoimmune diseases, such as multiple sclerosis. Patients with multiple sclerosis are often 
administered immunomodulatory and immunosuppressive drugs, such as interferon beta and 
cyclophosphamide. These therapies act broadly on the entire immune system with the 
unfortunate side effect of high infection rates. [83, 84] However, targeted therapeutic approaches 
that are antigen-specific would focus action on immune cells involved in disease and preserve 
the remainder of the immune system to maintain immune competency. Multiple sclerosis is 
modeled in mice using experimental autoimmune encephalomyelitis (EAE), wherein 
autoreactive CD4+ T cells recognize and respond to myelin epitopes. [43, 85] Following 
activation and proliferation, these T cells migrate to the central nervous system (CNS) and 
initiate inflammation, causing large influxes of immune cells that demyelinate axons, resulting in 
the observable loss of sensorimotor functions. Strategies to attenuate disease and establish 
durable immune tolerance focus on suppression of the activated autoreactive T cells.[86]  
Induction of an antigen-specific immune response is relatively complex, involving the 
interaction of multiple cell types. T cells first become activated based on signals received from 
antigen-presenting cells (APCs). [87] Consisting primarily of macrophages (MΦs) and dendritic 
cells (DCs), APCs internalize and digest proteins from the extracellular space, [80] generating 
peptides, or antigens that are preferentially loaded onto class II molecules of major 
histocompatibility complex (MHC) molecules for surface display. Antigen loaded onto MHC-II 
molecules is recognized only by CD4+ T cells that express the specific receptor. [18] The 
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number of T cells able to recognize a particular antigen is initially low. To shift the immune 
response, T cells specific for the particular antigen receive activation signals from co-stimulatory 
ligands which include CD80 and CD86 expressed by APCs. [19] CD40 interactions with T cells 
can also mature APCs to elicit stronger effector T cell responses. [88]  Engagement of only the T 
cell receptor complex without co-stimulation results in a state of T cell unresponsiveness. APCs 
may also express negative co-stimulatory molecules, such as PD-L1, or anti-inflammatory 
cytokines, such as IL-10 which have been shown to be critical for immune tolerance. [20, 48] 
Antigen-conjugated polymeric nanoparticles, such as those made with the biodegradable 
and biocompatible material, poly(lactide-co-glycolide) (PLG), have demonstrated the ability to 
induce immune tolerance in models of autoimmunity, allergic responses, and cell transplantation. 
[50, 81, 89] Intravenously delivered fluorescent PLG nanoparticles co-localized with MARCO-
positive and SIGN-R1-positive cells in the liver and spleen, suggesting selective uptake by 
APCs. Autoreactive T cells were reported to undergo apoptosis, anergy, and suppression by 
regulatory T cells [50] and the importance of IL-10 and PD-L1 for immune tolerance was 
established by several studies. [48, 90, 91] However, the fate of delivered antigen, the efficiency 
of antigen processing and T cell signaling, and the impact of antigen conjugation levels and 
nanoparticle dose remain key factors to be investigated. 
In this chapter, we investigate cellular and molecular tolerance mechanisms resulting from 
antigen-conjugated nanoparticle treatment. Initially, in vivo studies were performed to correlate 
amounts of antigen conjugation and nanoparticle dose with the severity of EAE disease course. 
Subsequently, several in vitro assays were used to investigate key steps including cell signaling 
upon internalization, MHC-restricted antigen presentation, and co-stimulatory expression. 
Tolerance induction was then evaluated by co-culturing nanoparticle-treated antigen-presenting 
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cells with autoreactive T cells. These studies provide mechanistic insights to assist in the 
development of nanoparticle-based therapeutics. 
4.3 Materials and Methods 
4.3.1 PLG nanoparticle synthesis and characterization 
PLG nanoparticles were prepared using a single emulsion-solvent evaporation method as 
previously described. [92] Briefly, PLG purchased from Lactel Absorbable Polymers 
(Birmingham, AL) was dissolved at 20% (w/v) in dichloromethane. Poly(ethylene-alt-maleic 
acid) (PEMA) was purchased from Polysciences, Inc. (Warrington, PA) and reconstituted in 
water at 1% (w/v). Sonicating a mixture of the PLG and PEMA produced nanoparticles, which 
following solvent evaporation, were washed three times and finally lyophilized in a solution of 
4% w/v sucrose and 3% w/v D-mannitol. Nanoparticle size and ζ-potential were measured using 
a Zetasizer Nano ZSP from Malvern Instruments Ltd (Worcestershire, UK). 
4.3.2 Conjugation of antigen or fluorophore onto PLG nanoparticles 
PLP139-151 and Ea52-68 were purchased from Genscript (Piscataway, NJ) and OVA323-339 was 
purchased from Celtek Peptides (Franklin, TN). FITC-cadaverine was purchased from Thermo 
Fisher Scientific (Waltham, MA). Lyophilized PLG nanoparticles were washed three times using 
phosphate-buffered solution (PBS) at pH 7.4. Approximately 4 mg of PLG nanoparticles was 
recovered and activated using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
purchased from Sigma-Aldrich (St. Louis, MO), at 16 mg/mL. Peptide or fluorophore was 
immediately added at the appropriate concentration to achieve desired higher or lower 
conjugation levels. The coupling reaction proceeded for 1 h under constant agitation. Uncoupled 
peptide was removed with three PBS washes. Total peptide conjugation was measured using the 




Female 6 to 8 week old SJL/J mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME) and Envigo (Indianapolis, IN). Female 6 to 8 week old C57BL/6 mice were 
purchased from Charles River Laboratories (Wilminton, MA). OT-II mice, transgenic for a TCR 
specific to OVA323-339, were purchased from the Jackson Laboratory and subsequently bred in-
house. All experiments involving mice were approved by the University of Michigan Committee 
on the Use and Care of Animals. 
4.3.4 EAE initiation and nanoparticle tolerance induction 
EAE disease was initiated as described previously.[85] Briefly, SJL/J mice were injected 
subcutaneously with an emulsion of PLP139-151 in complete Freund’s adjuvant. To induce 
tolerance, a single dose of either PLG-PLP-Hi or PLG-PLP-Lo was administered intravenously 7 
d after disease initiation. The control group was administered a single dose of PLG-OVA-Hi. 
Behavioral testing of mice was performed daily to determine clinical score, based on a 0-5 scale 
as follows: 0, healthy; 1, limp tail; 2, limp tail and impaired righting reflex; 3, hind-limp 
weakness; 4, hind-limb paralysis; and 5, moribund. 
4.3.5 Harvesting and culturing of APCs 
To obtain a primary population of APCs, bone marrow was harvested from the femurs and 
tibias of mice and differentiated in vitro. Cells were cultured in RPMI 1640 supplemented with 
10% FBS, 4mM L-glutamine, and 1% penicillin/streptomycin, all purchased from Life 
Technologies (Carlsbad, CA). Culturing media was further supplemented with either 20% L929 
conditioned media to obtain macrophages, or with 50 μM of 2-mercaptoethanol (Sigma-Aldrich, 
St. Louis, MO) and 20 ng/mL of GM-CSF purchased from PeproTech (Rocky Hill, NJ) to obtain 
dendritic cells. Media was replaced at 3 days and 6 days after initial culture. On Day 8, 
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macrophages were removed using Versene treatment and dendritic cells were obtained from 
suspension. APCs were seeded between 2.0 x 105 to 2.5 x 105 cells/mL in either 24-well 
untreated flat bottom cell culture plates or 96-well treated round bottom cell culture plates. APCs 
were activated with lipopolysaccharide (LPS) at 100 ng/mL to improve cell viability. 
4.3.6 Internalization assays 
Quenching of extracellular FITC was validated using APCs from C57BL/6 mice that 
were pre-treated for 30 minutes with 20 μg/mL of cytochalasin D, purchased from Life 
Technologies (Carlsbad, CA). PLG-FITC was administered to APCs at 1, 10, or 100 μg/mL. At 
several time intervals, APCs were collected. Following PBS wash, trypan blue was added at 1.2 
mg/mL to quench extracellular FITC molecules. Fluorescence was measured using a CyAn ADP 
Analyzer manufactured by Beckman Coulter (Brea, CA), and data was analyzed using FlowJo 
v10. Cellular events were gated using forward scatter and side scatter. FMO controls were then 
used to identify cells with positive signal.  
4.3.7 Cell signaling analysis of transcription factor activity 
The reporter library consisted of lentiviral constructs, each with a consensus binding 
sequence for a specific transcription factor driving expression of the firefly luciferase reporter. 
The process of identifying consensus binding sequences and determining reporter specificity has 
been described previously.[93] APCs were batch transduced with a single lentiviral reporter and 
seeded in black 96-well plates for a minimum of 48 hours. Cultures were replaced with fresh 
media containing LPS to improve cell viability, and D-luciferin purchased from Perkin Elmer 
(Waltham, MA). Cells were treated with either soluble antigen or peptide-conjugated 
nanoparticles and bioluminescence measurements were acquired at 2.5, 5, 8, 19, 24, and 28 h 
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post-treatment. A minimum of four technical repeats was used per treatment group for each 
lentiviral reporter, and experiments were repeated two to three times. 
4.3.8 Measuring antigen presentation and co-stimulation 
APCs from C57BL/6 mice were cultured in 24-well flat bottom plates were administered 
PLG-Eα-Hi or PLG-Eα-Lo at 1, 10, or 100 μg/mL. After 24h, APCs were collected and Fc 
receptors blocked with TruStain fcX, purchased from BioLegend (San Diego, CA). To detect 
antigen presentation, APCs were stained with αI-Ab-Ea52-68-FITC (clone eBioY-Ae) purchased 
from eBioscience (San Diego, CA). Simultaneously, co-stimulatory expression was measured by 
staining with αPD-L1-Brilliant Violet 421 (clone 10F.9G2), αCD80-phycoerythrin (PE) (clone 
16-10A1), αCD86-PE/Cy5 (clone GL-1), and αCD40-PE/Cy7, all purchased from BioLegend 
(San Diego, CA). Cell identity was confirmed through staining with αF4/80-APC-eFluor 780 
(clone BM8) or αCD11c-APC-eFluor 780, both purchased from eBioscience (San Diego, CA). 
Viability was confirmed using Annexin V-Pacific Blue, purchased from BioLegend (San Diego, 
CA). Fluorescence signal was measured and analyzed similarly to the internalization assays.  
4.3.9 T cell co-cultures with nanoparticle-treated APCs  
T cells were obtained from murine spleen and lymph nodes (axillary, inguinal, brachial) 
using MACS LS columns. Naïve T cells were purified from OT-II mice using the Naïve CD4+ T 
Cell Isolation Kit and autoreactive T cells were purified from SJL/J mice 7 days following EAE 
disease initiation using the CD4+ T Cell Isolation Kit, both manufactured by Miltenyi Biotec 
(San Diego, CA).  
Purified T cells were stained for 10 min at 37°C with 2.5 μM carboxyfluorescein 
succinimidyl ester (CFSE) purchased from Life Technologies (Carlsbad, CA). The staining was 
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immediately quenched with APC culturing media, supplemented with 1x non-essential amino 
acids, 1 mM sodium pyruvate, and 50 μM 2-mercaptoethanol.  
Before the addition of T cells, APCs were activated with 100ng/mL of LPS for improved 
viability and seeded in 96-well round bottom plates. Following 24h of either soluble peptide or 
nanoparticle treatment, culture media was replaced with fresh media containing CFSE-stained T 
cells at a 2:1 ratio of T cells to APCs. After 3 to 5 days, T cells were collected to measure CFSE 
fluorescence signal. 
Naïve T cells from OT-II mice were used for functional detection of antigen presentation 
following nanoparticle internalization. These T cells were co-cultured 3 days with APCs isolated 
from healthy C57BL/6 mice. Autoreactive T cells from EAE-immunized SJL/J mice were used 
to examine for tolerance induction. These T cells were co-cultured 5 days with APCs isolated 
from healthy SJL/J mice. Apoptosis was detected using Annexin V staining. Cytokine 
concentrations in the culture media were analyzed using ELISA kits from R&D Systems 
(Minneapolis, MN). 
4.3.10 Statistical analyses 
Comparisons between EAE disease courses of different treatment groups were analyzed by 
a Mann-Whitney test. Determination of transcription factors whose activities were significantly 
different due to nanoparticle-mediated rather than soluble antigen delivery was assessed for each 
measured time point by fitting normalized transcription factor activities to an empirical 
hierarchical Bayesian linear model using limma [94] independently for each biological repeat. 
Significant differences in co-stimulatory expression, T cell proliferation and apoptosis, and 
cytokine levels were identified using either a 1-way or 2-way ANOVA followed by the Tukey 




4.4.1 Peptide-conjugated PLG nanoparticles induce antigen-specific immune tolerance 
PLG nanoparticles were manufactured using an emulsion process and subsequently 
evaluated for size and charge. The average diameter was 538 ± 21 nm and average ζ-potential 
was −43 ± 8 mV. Following peptide conjugation, nanoparticles showed an increase in size 
relative to unmodified nanoparticles, suggesting the development of some nanoparticle 
aggregates. No major impacts on zeta potential was observed. Peptides of myelin proteolipid 
protein (PLP139-151), ovalbumin (OVA323-339), and I-Eα (Eα52-68) were chemically conjugated at 
multiple concentrations to yield two types of nanoparticles for each antigen, one with higher and 
one with lower levels of peptide as summarized in Table 4.1. The EAE disease model and in 
vitro studies of cells isolated from this model employed nanoparticles conjugated with PLP139-151 
and OVA323-339. Nanoparticles conjugated with Eα52-68 and OVA323-339 were used for in vitro 
mechanistic studies to examine antigen processing and presentation.  
Intravenous administration of a single 1.25 mg dose of PLG nanoparticles with higher 
conjugation of disease-relevant PLP139-151 (PLG-PLP-Hi) significantly reduced clinical score 
during the course of relapse-remitting EAE compared to PLG nanoparticles conjugated with 
disease-irrelevant OVA323-339 (PLG-OVA-Hi) which resulted in severe acute disease. (Fig 4.1a) 
Administering a single 2.0 mg dose of PLG nanoparticles with lower conjugation levels of 
PLP139-151 (PLG-PLP-Lo) had strong knock-down of clinical scores early, but resulted in 
moderate clinical scores later in the disease course. (Fig 4.1b) Interestingly, administering a 
single 2.0 mg dose of PLG-PLP-Hi led to durable immune tolerance throughout the disease 
course, suggesting the importance of both total peptide and total administered dose of 
nanoparticles for induction of immune tolerance. 
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Table 4.1 Amount of peptide conjugated to PLG nanoparticles. 
 Peptide Conjugation 
[μg/mg of PLG] 
PLG-OVA323-339-Hi 14.4 ± 1.7 
PLG-OVA323-339-Lo 7.6 ± 0.5 
PLG-PLP139-151-Hi 9.8 ± 2.5 
PLG-PLP139-151-Lo 4.1 ± 0.7 
PLG-Eα52-68-Hi 17.8 ± 2.0 







Figure 4.1 Peptide-conjugated nanoparticles induce antigen-specific tolerance to prevent 
EAE. Daily assessment of disease symptoms using mean clinical score following immunization 
against PLP139-151 to induce EAE disease. (a) SJL/J mice intravenously administered 1.25 mg of 
peptide-conjugated PLG nanoparticles. Mice treated with PLG-PLP-Hi had significant reduction 
of clinical scores compared to mice treated with PLG-OVA-Hi. (b) SJL/J mice intravenously 
administered 2.0 mg of peptide-conjugated PLG nanoparticles. Mice treated with either PLG-
PLP-Hi or PLG-PLP-Lo both had significantly lower scores compared to mice treated with PLG-
OVA-Hi. Additionally, scores of mice treated with PLG-PLP-Hi were significantly lower than 
those of mice treated with PLG-PLP-Lo (**p < 0.01, ***p < 0.001, ****p < 0.0001, Mann-
Whitney test). Each group had 5-6 mice and was representative of three separate experiments. 




4.4.2 Cell signaling response following nanoparticle internalization  
Nanoparticle internalization, a pre-requisite for antigen processing and presentation, was 
examined by administering PLG nanoparticles conjugated with fluorescein (PLG-FITC) to APCs 
for 24 h. Both MΦs and DCs exhibited high levels of fluorescence following quenching of 
extracellular fluorophores, indicating large amounts of nanoparticle internalization. (Figs 4.2a, 
b) To further confirm nanoparticle internalization, MΦs and DCs were treated with cytochalasin 
D to restrict cell internalization. Following treatment with PLG-FITC and quenching, these cells 
had low fluorescence signal, similar to that of untreated cells.  
The internalization kinetics were measured following treatment with a range of PLG-FITC 
doses. At a low dose of PLG-FITC (1 μg/mL), the percentage of APCs with nanoparticle 
internalization increased at a steady rate over 24h. Higher doses of PLG-FITC, at 10 and 100 
μg/mL, caused the percentage of APCs with nanoparticle internalization to increase 
exponentially within a few hours of treatment and level off by 24h. (Figs 4.2c, d) MΦs showed a 
moderate advantage over DCs in their internalization of PLG nanoparticles independent of dose 
administered. 
The quantity of nanoparticles internalized per cell was evaluated using mean fluorescent 
intensity (MFI). After 24h of PLG-FITC treatment at 1, 10, or 100 μg/mL, the MFI of MΦs was 
34.1 ± 2.3, 112.5 ± 13.1, or 301.7 ± 27.8, respectively. The MFI of DCs under the same dosing 
regimen yielded MFI values of 37.0 ± 3.8, 141.9 ± 36.9, or 268.3 ± 9.3. (Figs 4.2e, f) Overall, 
these studies indicated a strong correlation between the nanoparticle dose and the quantity of 
internalized nanoparticles. Taken together, these results indicate that MΦs and DCs had similar 





Figure 4.2 Macrophages and dendritic cells rapidly internalize PLG nanoparticles. Antigen-
presenting cells administered PLG nanoparticles surface-conjugated with fluorescein (FITC). 
Extracellular fluorescence was quenched using trypan blue before flow cytometry analysis. (a, b) 
High fluorescence intensity was observed in cells 24 h after PLG-FITC treatment. Cells 
administered PLG-FITC in the presence of cytochalasin D had low fluorescence intensity, 
equivalent to the intensity of cells not administered PLG-FITC. (c, d) The percentage of cells 
with detectable nanoparticle internalization and (e, f) the mean fluorescence intensity after 2 and 
24h of treatment with 1, 10, or 100 μg/mL of PLG-FITC. Macrophages in a, c, e and dendritic 




Dynamic activity profiles of immune-related transcription factor activity were used to 
identify signaling pathways activated for delivery of OVA323-339 antigen by nanoparticles relative 
to soluble peptide. The activity of 14 transcription factors was analyzed using a TRanscriptional 
Activity CEll aRray (TRACER).   Several members of the signal transducer and activator of 
transcription (STAT) family were examined, which showed PLG-OVA treatment significantly 
decreased STAT-1 activity in DCs and significantly increased STAT-3 activity relative to 
soluble OVA323-339 treatment in both cell types. (Fig 4.3a-d)The decrease in STAT-1 activity 
correlates with less signaling through the IFN-γ receptor, while the increase in STAT-3 activity 
indicates higher IL-10 receptor activity. Further transcription factor analysis included AP-1, NF-
KB, and RUNX1, all of which had increased activity in both cell types in response to PLG-OVA 
compared to soluble OVA323-339 treatment. (Fig 4.3e-j) The activity changes in these factors 






Figure 4.3 Cell signaling activity following soluble or nanoparticle-mediated antigen 
delivery. Dynamic activity of several transcription factors in the hours following APC treatment 
with either nanoparticle-conjugated (PLG-OVA-Lo or PLG-OVA-Hi) or soluble OVA323-339. (a, 
b) STAT-1 activity did not change in MΦs, but significantly decreased in DCs at later time 
points following treatment with nanoparticle-conjugated OVA323-339. (c, d) STAT-3 significantly 
increased in both MΦs and DCs administered nanoparticle-conjugated OVA323-339. (e-j) AP-1, 
NF-KB, and RUNX1 were all significantly increased following treatment with nanoparticle-
conjugated compared to soluble treatment of OVA323-339. Macrophages in a, c, e, g and dendritic 





4.4.3 Peptide-conjugated nanoparticles deliver functional antigen to APCs  
Functional availability of surface MHC-restricted antigen for T cell signaling was 
measured by co-culturing nanoparticle-treated APCs with naïve CD4+ T cells specific for 
OVA323-339. Activated MΦs and DCs were administered 100 μg/mL of blank or antigen-
conjugated nanoparticles, or an equivalent dose of soluble OVA323-339. The percentage of T cells 
undergoing proliferation was negligible in all conditions involving co-culture with MΦs. (Fig 
4.4a) T cells co-cultured with untreated DCs or DCs administered PLG nanoparticles also had 
negligible proliferation. (Fig 4.4b) However, administering soluble OVA323-339 resulted in 89.2% 
of T cells dividing, while administering PLG-OVA-Lo or PLG-OVA-Hi resulted in 94.9% or 
94.5% of T cells dividing, respectively. These results demonstrated the efficacy of antigen 
delivery from PLG nanoparticles to trigger a T cell response, as well as the greater potency of 





Figure 4.4 T cell signaling potential of macrophages and dendritic cells. T cell proliferation 
following 3d of co-culturing naïve T cells, isolated from OT-II transgenic mice, with (a) 
macrophages or (b) dendritic cells pre-treated 24h with either soluble OVA323-339, blank 
nanoparticles, or nanoparticles conjugated with high or low levels of OVA323-339. Data is 




We subsequently used a peptide of I-Eα (Eα52-68) to examine the APC surface for MHC-
restricted antigen. Similar to both OVA323-339 and PLP139-151, Eα52-68 forms complexes with MHC 
class II molecules for presentation on the APC surface to CD4+ T cells. The advantage of Eα52-68 
is the availability of a monoclonal antibody (Y-Ae) that only binds Eα52-68 when complexed to 
MHC, allowing identification of cell subpopulations participating in antigen presentation.[95] 
Detection of surface MHC-restricted antigen was dose-dependent with the administered amount 
of either free peptide or peptide-conjugated nanoparticle. After soluble Eα52-68 was administered 
at 0.1, 1, or 10 μg/mL for 24 h, the MΦ percentages with detectable MHC-restricted antigen 
were 0.9 ± 0.1%, 1.4 ± 0.1%, and 1.1 ± 0.1%, and the corresponding DC percentages were 0.6 ± 
0.1%, 2.7 ± 0.1%, and 15.1 ± 0.1%. (Figs 4.5a, b) These results reflect a positive correlation 
between amount of antigen administered and antigen presentation levels. When PLG-Eα-Lo was 
administered at 1, 10 or 100 μg/mL, the MΦ percentages with detectable MHC-restricted antigen 
were 1.3 ± 0.1%, 1.8 ± 0.1, and 3.8 ± 0.3% and the corresponding DC percentages were 0.4 ± 
0.1%, 1.8 ± 0.2%, and 19.4 ± 1.0%. (Figs 4.5c, d) Administering PLG-Eα-Hi at the same doses 
as PLG-Eα-Lo, MΦ percentages with detectable MHC-restricted antigen were 1.3 ± 0.1%, 2.0 ± 
0.1%, and 7.1 ± 0.4%. (Fig 4.5e) Similarly, DC percentages were 0.8 ± 0.1%, 3.2 ± 0.1%, and 
24.9 ± 1.4%. (Fig 4.5f) Both nanoparticle dose and levels of antigen conjugation to nanoparticles 
correlated with the percentage of cells with detectable MHC-restricted antigen. Although similar 
amounts of PLG-FITC was internalized among the APCs as seen in Figure 4.2, DCs were more 
efficient than MΦs for antigen processing and presentation. Moreover, comparing similar total 
quantities of antigen delivery, nanoparticle-mediated antigen delivery resulted in higher cell 





Figure 4.5. Dose-dependent correlation between antigen delivered and cell surface antigen 
presentation. Percentage of cells with detectable Eα52-68 loaded on major histocompatibility 
complex (MHC) class II molecules after 24h of treatment with (a, b) 0.1, 1, or 10 μg/mL of 
soluble Eα52-68, (c, d) 1, 10, or 100 μg/mL of PLG-Eα-Lo, or (e, f) 1, 10, or 100 μg/mL of PLG-
Eα-Hi. Macrophages in a, c, e and dendritic cells in b, d, f. Data show averages of three 





4.4.4 Reduced APC expression of positive co-stimulatory molecules 
APC expression of CD86, CD80, CD40, and PD-L1, co-stimulatory molecules influencing 
the T cell response, were evaluated alongside antigen presentation. The ability to identify APC 
subpopulations expressing MHC-restricted Eα52-68 enabled focusing analysis on cells exhibiting 
antigen presentation and thereby capable of signaling to T cells. Soluble Eα52-68 administered at 
increasing doses to MΦs resulted in no significant changes to co-stimulatory expression. 
However, DCs exhibited a modest, but significant increase in the percentage of CD86-positive 
cells when the dose of soluble Eα52-68 increased from 0.1 to 10 μg/mL. (Figs 4.6a-b)  
Treatment with peptide-conjugated nanoparticles had a more noticeable effect on APC co-
stimulatory expression. PLG-Eα-Lo administered at 100 μg/mL to MΦs significantly reduced 
CD86 and CD80 expression compared to their levels at either 1 or 10 μg/mL. (Fig 4.6c) 
However, PLG-Eα-Lo treatment did not significantly affect co-stimulatory expression in DCs. 
(Fig 4.6d) Interestingly, PLG-Eα-Hi elicited more significant reduction of co-stimulatory 
molecules at lower doses than PLG-Eα-Lo. Among MΦs, PLG-Eα-Hi reduced CD86 and CD80 
expression at 10 μg/mL compared to their levels at 1 μg/mL, and again at 100 μg/mL compared 
to their levels at both 1 and 10 μg/mL. (Fig 4.6e) Among DCs, administering PLG-Eα-Hi 
significantly reduced CD86 at 10 and 100 μg/mL compared to their levels at 1 μg/mL, although a 
significant increase in CD86 occurred between 10 μg/mL and 100 μg/mL. (Fig 4.6f) 
Additionally, PLG-Eα-Hi resulted in significant reduction of CD80 between 10 and 100 μg/mL 
compared to its levels at 1 μg/mL. Further, PLG-Eα-Hi reduced CD40 levels at 100 μg/mL 
compared to its levels at 1 and 10 μg/mL. Expression of the negative co-stimulatory molecule 
PD-L1 was unchanged in all treatment conditions. Nanoparticle doses exceeding 100 μg/mL 




Figure 4.6 Effects of peptide-conjugated nanoparticles on expression of cell surface 
molecules. (a, b) Increasing the dose of soluble Eα52-68 from 0.1 to 10 μg/mL had no detectable 
changes in MΦs, but a significant increase of CD86 was detected in DCs. (c, d) Higher doses of 
PLG-Eα-Lo significantly lower percentages of cells expressing CD86 and CD80 in MΦs 
compared to lower doses, but there were no significant differences in DCs. (e) Higher doses of 
PLG-Eα-Hi also led to significantly lower percentages of MΦs expressing CD86 and CD80 
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compared to lower doses. (f) Among DCs, higher doses of PLG-Eα-Hi resulted in significantly 
lower cell percentages expressing CD86, CD80, and CD40. No significant changes to PD-L1 
were detected following a dose increase of any treatment condition tested. (*p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001, 2-way ANOVA followed by the Tukey test for multiple 
comparisons). Macrophages in a, c, e and dendritic cells in b, d, f. Data show averages of three 





Collectively, these observations indicate that nanoparticle-mediated antigen delivery, 
particularly at the greater antigen loading (PLG-Eα-Hi), reduced expression levels of positive co-
stimulatory molecules involved in activating T cell effector responses. When Eα52-68 was 
administered directly to APCs, the subpopulations expressing MHC-restricted antigen showed no 
changes in co-stimulatory expression, even as the peptide dose was increased. However, the 
percentage of cells expressing positive co-stimulatory expression decreased with higher doses of 
peptide-conjugated nanoparticles, suggesting a critical role for nanoparticle-mediated peptide 
delivery to reduce APC co-stimulation. Notably, the trends in co-stimulatory expression 
following antigen-conjugated PLG nanoparticle administration were observed only on the cell 
subpopulations expressing antigen identified through the use of Eα52-68 and the corresponding Y-
Ae antibody.  
4.4.5 Proliferation, apoptosis, and cytokine levels in co-cultures with T cells  
T cell activity was examined following isolation from mice immunized against PLP139-151 
and subsequent co-culture with nanoparticle-treated APCs. T cells co-cultured with MΦs 
administered 100 μg/mL of either PLG-PLP-Lo or PLG-PLP-Hi had reduced levels of 
proliferation compared to untreated MΦs. No significant changes in proliferation were measured 
in T cells co-cultured with MΦs administered soluble PLP139-151 or unmodified PLG compared to 
untreated MΦs. (Fig 4.7a) T cells co-cultured with DCs administered either PLP139-151, 
unmodified PLG, PLG-PLP-Lo, or PLG-PLP-Hi had similar levels of proliferation as T cells co-
cultured with untreated DCs. (Fig 4.7b) Levels of interleukin-10 (IL-10), an anti-inflammatory 
cytokine, were undetectable among T cells co-cultured with MΦs regardless of the treatment. 
(Fig 4.7c) However, levels of IL-10 significantly increased among T cells co-cultured with DCs 
treated with PLG or PLG-OVA-Hi compared to treatment with PLP139-151. The IL-10 levels were 
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more significantly increased among T cells co-cultured with DCs administered PLG conjugated 
with disease-relevant antigen (PLG-PLP-Hi and PLG-PLP-Lo) compared to T cells co-cultured 
with DCs administered PLP139-151. (Fig 4.7d). 
T cell fate following co-culture with DCs was further evaluated for apoptosis. The 
percentage of T cells undergoing apoptosis did not significantly change when co-cultured with 
DCs administered increasing doses of PLG-PLP-Lo (Fig 4.8a). However, treatment with 
increasing doses of PLG-PLP-Hi resulted in a significant increase in T cell apoptosis at 100 
μg/mL compared to 1 μg/mL of PLG-PLP-Hi. (Fig 4.8b). Results of the T cell co-culture studies 
suggest different tolerance mechanisms, which include proliferation, apoptosis, and cytokine 






Figure 4.7 Changes in T cell proliferation and anti-inflammatory cytokine expression. (a) T 
cells isolated from mice immunized against PLP139-151 had significantly reduced proliferation 
following 5 d of co-culture with MΦs administered 100 μg/mL of either PLG-PLP-Hi or PLG-
PLP-Lo compared to MΦs administered no treatment. (b) T cell proliferation was not 
significantly changed in co-culture with DCs administered either soluble antigen or nanoparticle 
treatment. (c) IL-10 was largely undetectable in T cell co-cultures with MΦs. (d) T cells co-
cultured with DCs treated with nanoparticles had significant increases of IL-10 compared to DCs 
administered soluble PLP139-151. The increase of IL-10 was more significant when DCs were 
treated with nanoparticles conjugated with PLP139-151, the T cell-specific antigen. (*p < 0.05, 
***p < 0.001, ****p < 0.0001, 1-way ANOVA followed by the Tukey test for multiple 





Figure 4.8 Effects of nanoparticle dose and antigen conjugation levels on T cell apoptosis. T 
cells isolated from mice immunized against PLP139-151 and co-cultured 5 d with DCs 
administered (a) PLG-PLP-Lo or (b) PLG-PLP-Hi. Increasing the nanoparticle dose of PLG-
PLP-Lo had no significant difference in the percentage of T cells with positive Annexin V 
staining, indicating apoptosis. However, increasing the nanoparticle dose of PLG-PLP-Hi from 1 
to 100 μg/mL resulted in significant increase of the percentage of T cells with positive Annexin 
V staining. Data show averages of two to three measurements ± standard error of mean (SEM). 





Peptide-conjugated nanoparticles have been used by several groups to prevent or treat EAE 
via a targeted, antigen-specific approach.[76, 81, 92] Consistent with these reports, herein, we 
found nanoparticles conjugated with disease-relevant peptide (PLP139-151) significantly improved 
EAE prognosis compared to nanoparticles conjugated with disease-irrelevant peptide (OVA323-
339). Our low nanoparticle dose (1.25 mg) did not provide the complete knock-down of EAE 
disease score as was seen with the high nanoparticle dose (2.0 mg). We further explored the 
impact of antigen conjugation levels, observing EAE relapse in later stages of the disease course 
following treatment with PLG-PLP-Lo. This relapse was abrogated by treatment with PLG-PLP-
Hi, which contained approximately twice the amount of PLP139-151. EAE relapses have been 
reported to result from epitope spreading, when the immune system recognizes an increasing set 
of myelin epitopes. [96, 97] Previous comparisons of CNS cell populations following treatment 
with PLG-PLP for EAE showed a reduction of total lymphocytes, total APCs, MΦs, and DCs 
relative to treatment with PLG-OVA.[92] It is likely the tolerance induction by PLG-PLP-Hi was 
more effective to curtail the immune response during early stages of EAE compared to PLG-
PLP-Lo, which prevented the generation of epitope spreading and the subsequent relapse. 
Many differences in transcription factor activity were detected between APCs administered 
soluble antigen and APCs administered antigen-conjugated nanoparticles. We examined several 
members of the STAT protein family, which play major roles in immune regulation. [98] STAT-
1 activation is well-known for mediating interferon signaling to promote inflammation, while 
STAT3 has been reported to negatively regulate interferon responses. [99] We observed a 
decrease in STAT-1 activity along with an increase of STAT-3 activity, suggesting cell 
internalization of antigen conjugated to nanoparticles suppressed interferon-related cell 
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signaling. We also examined the activity of RUNX1 which synergizes with C/EBPβ and PU.1 to 
drive expression of microRNA-142 which regulates immunity. [100] However, when innate 
immune receptors such as TLR4 are triggered, AP-1 and NF-KB activity increases and 
negatively regulate microRNA-142 expression. We hypothesize that the higher intensity of 
RUNX1 detected would suggest a compensatory response of APCs to the AP-1 and NF-KB 
activity resulting from nanoparticle treatment. However, the complex interplay of intracellular 
immune signaling pathways will require further investigation to identify those pathways driving 
the phenotypic response. 
Both MΦs and DCs internalized large amounts of nanoparticles, yet DCs showed much 
higher efficiency for antigen presentation. Additionally, when equivalent amounts of total 
antigen was delivered, higher levels of antigen presentation were detected on cells administered 
nanoparticles relative to soluble treatment. DCs have a reputation as the primary APCs for T cell 
signaling, due to DCs having a higher surface density of MHC-II molecules compared to MΦs. 
[21] Peptide-MHC complexes on the cell surface are crucial for signaling to T cells,[101] which 
may explain the high rates of naïve T cell proliferation observed in co-cultures with DCs not 
seen in co-cultures with MΦs. The studies with Eα52-68 revealed lower percentages of APCs with 
detectable MHC-restricted antigen presentation compared to PLG-Eα treatments that delivered 
similar amounts of antigen. Moreover, nearly every cell internalized nanoparticles, but only a 
portion had detectable levels of antigen presentation. Studies of class I presentation have also 
reported low efficiency for antigen presentation wherein a 100-fold increase in the quantity of 
antigen delivered resulted in a less than two-fold increase of antigen presentation.[102] The class 
I and class II presentation pathways differ primarily by whether antigen escapes the endosome 
into the cytosol, or remains within the endosome until reaching the lysosome. Interestingly, using 
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a reducible chemical bond to link antigen with polymer nanoparticles resulted in a significant 
increase in class I antigen presentation compared to using a non-reducible bond.[103] Therefore 
tuning the linker strength between the antigen and polymer may have implications to augment 
class II presentation from nanoparticles. 
Co-culturing autoreactive T cells with nanoparticle-treated APCs resulted in several 
indications of immune suppression. The onset of EAE occurs via autoreactive T cells producing 
large amounts of pro-inflammatory cytokines, including IFNγ.[104] However, EAE disease 
course can be tempered by the stimulated production or addition of IL-10.[76, 105] 
Administering either PLG-PLP-Hi or PLG-PLP-Lo to APCs likely resulted in reduced 
expression of co-stimulatory molecules as seen with administering PLG-Eα-Lo and PLG-Eα-Hi. 
When these APCs were co-cultured with autoreactive T cells, the presence of antigen without co-
stimulation caused T cells to enter a state of unresponsiveness.[106] We detected this state by an 
absence of T cell proliferation and increase in T cell apoptosis. The increases in IL-10 
concentration further suggest the activation of tolerance signaling pathways.  
Collectively, these results identify cell types and mechanisms contributing to antigen-
specific tolerance in animal models of R-EAE following nanoparticle treatment. We correlated 
the delivery of antigen-conjugated nanoparticles with surface levels of class II antigen 
presentation, expression of positive and negative co-stimulatory factors, and subsequent T cell 
proliferation or apoptosis. Furthermore, the assays used herein provide useful tools to evaluate 
the efficiency of nanoparticle designs for antigen delivery, APC phenotype shifting, and T cell 
activation, which may be useful to identify future formulations with greater potential to induce 









Chapter 5: The Role of NF-KB Signaling Due to Antigen-Coupled Nanoparticles or Cells 
Administered for Antigen-Specific T Cell Tolerance 
5.1 Abstract 
Reintroducing self-reactive antigen coupled to an antigen delivery vehicle has been shown 
to induce rapid and long-lived immune tolerance in models of autoimmune diseases. Several 
platforms have emerged as antigen delivery vehicles, including donor cells and synthetic 
nanoparticles. Both types of vehicles coupled with OVA323-339 antigen were administered to 
antigen-presenting cells prior to co-culture with OVA323-339-specific T cells. Macrophages were 
not sensitive to vehicle type, however, treating dendritic cells with antigen-coupled splenocytes 
(SP-OVA) reduced T cell proliferation and expression of IL-2Rα while enhancing T cell 
apoptosis and expression of L-selectin, indicators of tolerance. Inhibiting NF-KB signaling 
activity in macrophages led to major changes in the T cell response, but NF-KB disruption in 
dendritic cells had minimal effects. Signaling activity in antigen-presenting cells following 
antigen delivery was measured using TRanscriptional Activity CEll aRray (TRACER). Network 
analysis showed NF-KB played a critical role for maintaining network connectivity in 
macrophages. Moreover, the activity of transcription factors, PPAR and CEBP, were shown to 
be highly interconnected following treatment with SP-OVA which suggests their activity may 




Self-reactive T cells that respond to autoantigens are normally found in the healthy T cell 
repertoire. Stringent T cell activation barriers are typically sufficient to maintain tolerance, but 
autoimmunity may still occur in instances such as following an infection that introduces 
pathogenic antigen cross-reactive with autoantigens. [107, 108] Activated T cells can be 
characterized by rapid proliferation, high expression of CD25 (IL-2Rα chain), and low 
expression of CD62L (L-selectin). [109] Cytokine expression is also an important indicator of T 
cell response, as increased GM-CSF levels have been implicated in T cell-mediated autoimmune 
pathogenesis, while IL-10 secretion assists in suppressing autoimmune responses. [32, 110] 
Typical autoimmune treatments have focused on global immune suppression, however the 
harmful side effects from disrupting immune competency has provided strong motivation for 
developing antigen-specific interventions. These approaches involve reintroducing an 
autoantigen in such a way that skews the immune response against the autoantigen towards 
tolerance. [111] One of the earliest antigen-specific approaches developed was hyposensitization 
therapy to bring about allergen desensitization. [112] Low doses of allergen were subcutaneously 
injected directly into the patient, and over time, the dose was slowly increased. While effective, 
the extended treatment window and risk for anaphylaxis limited its clinical adoption. 
The use of delivery vehicles to reintroduce autoantigens has been effective to induce rapid 
and long-lived immune tolerance. One type of vehicle is a donor cell, such as splenocytes, onto 
which autoantigens have been attached via chemical coupling which has induced tolerance in 
models of autoimmunity, allergy, and transplant rejection. [113] Another form of antigen 
delivery vehicle is a synthetic nanoparticle. Nanoparticles represent a versatile platform that can 
be modified in size and shape to target specific tissues and cell types. Functional groups on the 
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nanoparticle surface also allow for autoantigen attachment via chemical coupling and these 
antigen-coupled nanoparticles have also induced tolerance in models of autoimmunity. [4] 
Both cell- and nanoparticle-mediated antigen delivery have demonstrated ability to induce 
tolerance, but direct comparisons of their mechanisms of action have yet to be explored. To 
effect tolerance induction, donor cells represent a more desirable delivery vehicle, as the immune 
system has many inherent homeostatic strategies to recognize cells and suppress an immune 
response. [114] The advantage of nanoparticles as a delivery vehicle is their ease of synthesis 
and storage. However, as a relatively inert platform, nanoparticles likely function primarily as an 
antigen depot, engaging tolerance mechanisms limited in scope to the antigen presentation 
process.  
The following investigation applies an in vitro model of T cell activation to examine the 
impact of different vehicles for delivering antigen and inducing tolerance. Antigen-coupled cells 
(SP-OVA) or nanoparticles (PLG-OVA) are administered to antigen-presenting cells (APCs), 
either macrophages or dendritic cells, prior to their co-culture with activated T cells. Following 
co-culture, the T cell response is analyzed and the co-culture environment is profiled for 
cytokine expression. Using TRanscriptional Activity CEll aRray (TRACER), we measure the 
activity of immune-related transcription factors in APCs following antigen treatment. The results 
are used to construct networks that infer interactions among the transcription factors measured. 
Comparing the network activity of cells following antigen delivery will reveal common or 




5.3 Materials and Methods 
5.3.1 Mice 
Female 6 to 12 week old C57BL/6 mice were purchased from Charles River Laboratories 
(Wilminton, MA). OT-II mice, transgenic for a TCR specific to OVA323-339, were purchased 
from the Jackson Laboratory and subsequently bred in-house. All experiments involving mice 
were approved by the University of Michigan Committee on the Use and Care of Animals.  
5.3.2 Preparation of donor splenocytes 
Spleens from healthy C57BL/6 mice were harvested and passed through a 100 μm nylon 
membrane to generate a single cell suspension. After RBC lysis, cells were washed with 
phosphate buffer solution (PBS) and reconstituted at 3.2 x106 cells/mL. 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide and OVA323-339 were added at final concentrations of 30 
mg/mL and 1 mg/mL, respectively. Chemical reaction proceeded for 1 h at 4°C under constant 
agitation. Cells were then washed three times with PBS and filtered through a 70 μm nylon 
membrane. 
5.3.3 Preparation of nanoparticles 
PLG nanoparticles were prepared using a single emulsion-solvent evaporation method as 
previously described. [92] Briefly, PLG purchased from Lactel Absorbable Polymers 
(Birmingham, AL) was dissolved at 20% (w/v) in dichloromethane. Poly(ethylene-alt-maleic 
acid) (PEMA) was purchased from Polysciences, Inc. (Warrington, PA) and reconstituted in 
water at 1% (w/v). Sonicating a mixture of the PLG and PEMA produced nanoparticles, which 
following solvent evaporation, were washed three times and finally lyophilized in a solution of 
4% w/v sucrose and 3% w/v D-mannitol. Nanoparticle size and ζ-potential were measured using 
a Zetasizer Nano ZSP from Malvern Instruments Ltd (Worcestershire, UK). 
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Lyophilized PLG nanoparticles were washed three times using PBS. Approximately 4 mg 
of PLG nanoparticles was recovered and activated using 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) at 16 mg/mL. OVA323-339 was immediately added at 1 mg/mL. The coupling 
reaction proceeded for 1 h under constant agitation. Uncoupled peptide was removed with three 
PBS washes.  
5.3.4 T cell co-cultures with pre-treated APCs 
A primary population of macrophages and dendritic cells was obtained as described 
previously. [90, 115] Briefly, bone marrow was harvested from femurs and tibias of C57BL/6 
mice and differentiated in vitro. Between 8 to 10 days following harvest, cells were seeded at 
approximately 2.5 x 105 cells/mL in 60 mm untreated dishes and activated with 
lipopolysaccharide (LPS) at 100 ng/mL. The next day, cells were treated with 10 μg/mL of free 
peptide, 100 μg/mL of peptide-conjugated nanoparticles, or a 5:1 ratio of peptide-conjugated 
splenocytes to cells for 24 h before co-culturing with naïve T cells. BAY 11-7085, a small 
molecule targeting NF-KB activity was purchased from Cayman Chemical (Ann Arbor, MI) and 
used at 50 μM. 
Naïve T cells were obtained from spleen and lymph nodes (axillary and inguinal) of OT-II 
mice using the Naïve CD4+ T Cell Isolation Kit, according to manufacturer specifications 
(Miltenyi Biotec, San Diego, CA). Purified T cells were stained with carboxyfluorescein 
succinimidyl ester (CFSE) purchased from Life Technologies (Carlsbad, CA) and mixed at a 2:1 
ratio with either macrophages or dendritic cells in RPMI 1640 supplemented with 10% FBS, 
4mM L-glutamine, 1x non-essential amino acids, 1 mM sodium pyruvate, and 50 μM 2-
mercaptoethanol. Cells were seeded at 6.0 x 105 cells/mL in 24-well plates pre-treated for 2 h 
with αCD3 (10 ng/mL) and αCD28 (2 ng/mL). 
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Cells were collected after 4 days of culture for flow analysis. Fc receptors were first 
blocked with TruStain fcX before staining with L-selectin-APC, IL-2Rα-PE, and CD4-APC-
eFluor 780 (eBioscience). Viability was measured using Annexin V-Pacific Blue. Except when 
indicated, all flow antibodies were purchased from BioLegend (San Diego, CA). Fluorescence 
signal was measured using a CyAn ADP Analyzer manufactured by Beckman Coulter (Brea, 
CA), and data was analyzed using FlowJo v10. Cellular events were gated using forward scatter 
and side scatter. FMO controls were then used to identify cells with positive signal. Cytokine 
concentrations in the culture media were analyzed using ELISA kits from R&D Systems 
(Minneapolis, MN). 
5.3.5 TRACER experiments 
Cells were aliquoted for separate batch infection with each lentiviral reporter. One μL of 
virus at approximately 1 x 109 IU/mL was administered per 25,000 cells. Cell and virus mixtures 
were seeded into black 96-well plates at 2.5 x 106 cells/mL and cultured for at least 48 h.  Fresh 
media was replaced containing 1 mM D-luciferin (Perkin Elmer) and 100 ng/mL 
lipopolysaccharide (Sigma). Bioluminescence measurements were acquired at 2.5, 5, 8, 18, 24, 
and 27 h post-seeding using an IVIS Lumina LTE camera system (Perkin Elmer, Waltham, MA, 
USA). A minimum of three technical repeats was performed for each reporter. 
5.3.6 Network analysis 
Network analysis of TRACER measurements was performed using NTRACER, as 
described previously. [93] Briefly, normalized activity measurements were mean centered and an 
initial net topology was inferred using several linear and non-linear techniques. The network 
architecture was optimized with CellNOptR and a total of 500 runs was performed. Edge 
significance was determined by comparing the number of edge occurrences in the 500 optimized 
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networks to 500 networks generated from permutation samples from the same data. Significance 
was determined by a p-value of 10-6. Features were selected from the top 10% of significant 
edges at each set of time points to ensure high-quality edge selection. Networks were visualized 
using the R package, iGraph. 
5.4 Results 
5.4.1 Antibody stimulation activates T cells in co-culture with treated APCs 
Macrophages administered different treatments were subsequently co-cultured with naïve T 
cells isolated from OT-II mice. In the absence of stimulating antibodies (αCD3 and αCD28), T 
cells had low expression levels of IL-2Rα, an activation marker, and high levels of L-selectin, an 
inactivation marker following co-culture with untreated macrophages. (Fig 1a, b) The presence 
of stimulating antibodies resulted in T cell activation, as measured by a significant increase of 
IL-2Rα, when either soluble OVA or BAY 11-7085 (a compound that prevents NFkB activation) 
was used to treat macrophages. L-selectin was significantly decreased among T cells co-cultured 
with macrophages treated with BAY 11-7085. T cell apoptosis, measured by Annexin V, did not 
change in response to stimulating antibodies or macrophage treatment with soluble OVA, but 
stimulating antibodies and macrophages treatment with BAY 11-7085 resulted in a significant 
increase of T cell apoptosis. (Fig 1c) Dilution of carboxyfluorescein succinimidyl ester (CFSE) 
to indicate T cell proliferation was low in the absence of stimulating antibodies. However, 
proliferation increased dramatically when stimulating antibodies were added, and proliferation 
was moderately higher when macrophages were treated with OVA compared to BAY 11-7085. 
(Fig 1d) 
Naïve T cells were also co-cultured with dendritic cells receiving various treatments. In the 
absence of stimulating antibodies, T cells had low IL-2Rα and high L-selectin expression 
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following co-culture with untreated dendritic cells. (Fig 1e, f) The presence of stimulating 
antibodies, regardless of dendritic cell treatment, resulted in a significant increase of IL-2Rα and 
a decrease of L-selectin, signifying T cell activation. A small significant increase of T cell 
apoptosis occurred in the presence of stimulating antibodies and dendritic cells treated with 
soluble OVA compared to the absence of stimulating antibodies or treating dendritic cells with 
BAY 11-7085. (Fig 1g) T cell proliferation increased dramatically when stimulating antibodies 
were present, with negligible differences between T cells co-cultured with dendritic cells 
receiving soluble OVA or BAY 11-7085 treatment. (Fig 1h) 
These studies confirmed the use of stimulating antibodies for mimicking T cell activation 
and also described the impact of treating APCs with BAY 11-7085 to inhibit NF-KB signaling 
activity. In co-culture with macrophages or dendritic cells, T cells had low IL-2Rα and high L-
selectin expression in the absence of antibody stimulation, which were reversed when 
stimulating antibodies were added. Interestingly, pre-treatment of macrophages but not dendritic 
cells with BAY 11-7085 had a significant impact on expression of L-selectin, apoptosis, and 
proliferation of T cells. This difference suggests a more critical role of NF-KB signaling in 
macrophages compared to dendritic cells for promoting T cell entry into lymph nodes, viability, 





Figure 5.1 T cell response following antibody stimulation in co-culture with treated APCs. Co-
culture of T cells with (a-d) macrophages or (e-h) dendritic cells administered the indicated 
treatment combinations. T cell expression of IL-2Rα in a, e, T cell surface expression of L-
selectin in b, f, T cell apoptosis in c, g, and T cell proliferation in d, h. (*p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001, 1-way ANOVA followed by the Tukey test for multiple 
comparisons). Data show averages of three measurements ± standard error of mean (SEM) or 





5.4.2 Cytokine profile from co-cultures of T cells and treated APCs 
The co-culture cytokine profile revealed a strong sensitivity of macrophage treatment with 
BAY 11-7085. Naïve T cells co-cultured with untreated macrophages in the absence of 
stimulating antibodies had undetectable levels of GM-CSF, IFN-γ, and IL-10. (Fig 2a-c) The 
presence of stimulating antibodies and macrophages treated with soluble OVA resulted in a 
small increase of IFN-γ, although GM-CSF and IL-10 expression levels were still unchanged. A 
notable increase of GM-CSF, IFN-γ, and IL-10 was measured in co-cultures of T cells and 
macrophages treated with BAY 11-7085 in the presence of stimulating antibodies. 
Stimulating antibodies and treatment of dendritic cells both influenced the cytokine profile 
in the co-culture environment. In the absence of stimulating antibodies, T cells co-cultured with 
untreated dendritic cells had undetectable levels of GM-CSF, IFN-γ, and IL-10. (Fig 2d-f) 
Adding stimulating antibodies and treating dendritic cells with soluble OVA resulted in 
significant increases of the measured cytokine levels. A significant increase of these three 
cytokines was also seen, although to a lesser extent, in co-cultures of T cells and dendritic cells 





Figure 5.2 Cytokine profile of T cells following antibody stimulation in co-culture with treated 
APCs. Cytokine expression levels in co-cultures of T cells and (a-c) macrophages or (d-f) 
dendritic cells administered the indicated treatment combinations. GM-CSF in a, d, IFN-γ in b, 
e, and IL-10 in c, f. (*p < 0.05, **p < 0.01, ****p < 0.0001, 1-way ANOVA followed by the 
Tukey test for multiple comparisons). Data show averages of three measurements ± standard 





5.4.3 Role of antigen delivery vehicle on T cell response 
The impact of delivering antigen to macrophages from different vehicles was examined via 
co-culture with naïve T cells in the presence of stimulating antibodies. IL-2Rα expression on T 
cells did not change significantly when macrophages were treated with PLG-OVA compared to 
soluble OVA. (Fig 3a) However IL-2Rα levels were significantly higher on T cells co-cultured 
with macrophages treated with SP-OVA relative to PLG-OVA. Interestingly, macrophage 
treatment with both SP-OVA and BAY 11-7085 resulted in a significant decrease of IL-2Rα 
expression by T cells compared to treating macrophages with both BAY 11-7085 and either 
soluble OVA or PLG-OVA. L-selectin expression did not change significantly due to different 
delivery vehicles, although L-selectin expression on T cells was generally lower when 
macrophages were treated with BAY 11-7085. (Fig 3b) T cell apoptosis was also not 
significantly affected by the different delivery vehicles but was notably higher when 
macrophages were treated with BAY 11-7085. (Fig 3c) T cell proliferation was not markedly 
changed in response to the different antigen delivery vehicles, but both BAY 11-7085 and either 
PLG-OVA or SP-OVA treatment of macrophages resulted in a moderate decrease of T cell 
proliferation. (Fig 3d) 
T cell co-cultures were also used to examine the impact of different antigen delivery 
vehicles on dendritic cells. T cell expression of IL-2Rα was high when dendritic cells were 
treated with soluble OVA or PLG-OVA, but treating dendritic cells with SP-OVA resulted in a 
significant decrease of IL-2Rα expression. (Fig 3e) Additionally treating dendritic cells with 
BAY 11-7085 alongside the delivery vehicles resulted in similar trends to IL-2Rα expression. L-
selectin expression on T cells was similar between co-cultures with dendritic cells treated soluble 
OVA or PLG-OVA, but treating dendritic cells with SP-OVA resulted in a significant increase of 
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L-selectin. (Fig 3f) Interestingly, the addition of BAY 11-7085 reversed the trend of L-selectin 
expression leading to a significant decrease when dendritic cells were treated with SP-OVA 
compared to soluble OVA. T cell apoptosis increased significantly when dendritic cells were 
treated with PLG-OVA compared to soluble OVA. (Fig 3g) Apoptosis was further increased in T 
cells co-cultured with dendritic cells treated SP-OVA. These trends in apoptosis were largely 
similar when dendritic cells were additionally pre-treated with BAY 11-7085. T cell proliferation 
was moderately attenuated in co-culture with dendritic cells treated with SP-OVA compared to 
soluble OVA or PLG-OVA. (Fig 3h) This attenuation due to SP-OVA was eliminated when 
dendritic cells were additionally pre-treated with BAY 11-7085. 
Different vehicles for antigen delivery had negligible impact on T cells when applied via 
macrophages. In contrast, dendritic cells treated with SP-OVA compared to soluble OVA or 
PLG-OVA elicited T cell changes consistent with tolerance, such as lower levels of IL-2Rα 
expression and proliferation, and higher levels of L-selectin expression and apoptosis. When NF-
KB signaling was inhibited in dendritic cells, the changes to T cell response brought on by 
different antigen delivery vehicles were still maintained, indicating redundancies or alternate 
signaling pathways used by dendritic cells to effect T cells. Interestingly, disruption of NF-KB 
signaling in macrophages led to dramatic changes in T cell response including decreased L-





Figure 5.3 T cell sensitivity to APCs treated with different antigen delivery vehicles. Co-culture 
of T cells with (a-d) macrophages or (e-h) dendritic cells administered the indicated treatment 
combinations. T cell expression of IL-2Rα in a, e, T cell surface expression of L-selectin in b, f, 
T cell apoptosis in c, g, and T cell proliferation in d, h. (*p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001, 2-way ANOVA followed by the Sidak test for multiple comparisons). Data 






5.4.4 Role of antigen delivery vehicle on co-culture cytokine profile 
The cytokine profile resulting from co-culture of T cells and macrophages showed 
negligible differences due to antigen delivery vehicle but a strong influence of NF-KB signaling 
activity. Expression of GM-CSF, IFN-γ, and IL-10 were detected at low concentrations in co-
cultures of T cells and macrophages treated either soluble OVA, PLG-OVA, or SP-OVA. (Fig 
4a-c) When macrophages were additionally treated with BAY 11-7085, expression levels of 
these three cytokines increased substantially. 
Co-cultures of T cells and dendritic cells produced cytokine profiles indicating the 
influence of both antigen delivery vehicle and NF-KB signaling. GM-CSF expression was 
unaffected by the vehicle delivering antigen to dendritic cells. (Fig 4d-f) However, lower GM-
CSF levels were measured when dendritic cells were treated with BAY 11-7085 in addition to 
either soluble OVA or SP-OVA. Treating dendritic cells with SP-OVA compared to soluble 
OVA or PLG-OVA resulted in a significant reduction of IFN-γ that was reversed in the context 
of BAY 11-7085 treatment. Expression of IL-10 was also unaffected by the antigen delivery 
vehicle. However, additional treatment of dendritic cells with BAY 11-7085 reduced overall IL-







Figure 5.4 Cytokine expression in co-cultures of T cells and APCs treated with different antigen 
delivery vehicles. T cells co-cultured with (a-c) macrophages or (d-f) dendritic cells 
administered the indicated treatment combinations. GM-CSF in a, d, IFN-γ in b, e, and IL-10 in 
c, f. (*p < 0.05, **p < 0.01, ****p < 0.0001, 2-way ANOVA followed by the Sidak test for 






5.4.5 Comparison of dynamic TF activity between antigen delivery vehicles 
TRACER was used to examine differences in APC signaling activity resulting from antigen 
delivery by different vehicles. Macrophages had a total of 50% (7/14) of examined factors that 
were significantly different between PLG-OVA and SP-OVA treatment. (Fig 5a) Of these 
factors, five were similarly different between PLG-OVA and SP-OVA treatment in dendritic 
cells. (Fig 5b) These transcription factors may be part of a common mechanism of APCs in 
response to antigen-coupled splenocyte or nanoparticle treatment. There were an additional 4 
factors whose dynamic activity in dendritic cells was significantly different between PLG-OVA 
and SP-OVA treatment, which may be part of a cell-specific response. The majority of 
transcription factors in dendritic cells following SP-OVA treatment had reduced activity over 






Figure 5.5 Dynamic transcription factor activity of APCs following antigen treatment. TRACER 
measurements of (a) macrophages or (b) dendritic cells in the hours following treatment with 
PLG-OVA or SP-OVA. Significance tests compared the PLG-OVA and SP-OVA treatments 
within each cell type. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, normalized 
activities were fitted to an empirical hierarchical Bayesian linear model). Data show averages of 




5.4.6 Inference networks of TF activity between antigen delivery vehicles 
Signaling networks were constructed using inference methods to analyze the TRACER 
studies and identify potential interactions among the transcription factors examined. The 
networks resulting from macrophages and dendritic cells treated with PLG-OVA depicted the 
majority of transcription factors with few interaction partners and a few key transcription factors 
serving as bridges to link the entire network together. (Fig 6a, b) These linking factors included 
NF-KB and AP-1 in macrophages and RUNX1, IRF-1, and AP-1 in dendritic cells, which are 
likely important signaling molecules to determine cell activity and response to PLG-OVA 
treatment. Networks built from macrophages and dendritic cells treated with SP-OVA appeared 
more highly inter-connected compared to networks built from the PLG-OVA response. (Fig 6c, 
d) NF-KB, PPAR, and AP-1 in macrophages and CEBP, IRF-1, and AP-1 in dendritic cells were 
among the more highly inter-connected nodes. From these network diagrams, the critical role of 
NF-KB in macrophage signaling was apparent. Removing NF-KB from either macrophage 
network would sever interactions among many transcription factors, creating several disparate 
networks. In comparison, removing NF-KB from the networks of dendritic cells would not 
substantially affect the interactions between the remaining transcription factors. These networks 
help explain the major changes in T cell response when macrophages compared to dendritic cells 





Figure 5.6 Network analysis of TRACER studies. Inference networks of transcription factor 
interactions following (a, b) PLG-OVA or (c, d) SP-OVA treatment. Macrophages in a, c and 






We were interested to use stimulated naïve T cells as a surrogate for self-reactive T cells to 
detect differences in their responses to antigen delivery vehicles. T cell stimulation with 
αCD3/αCD28 has been widely used to expand naïve populations of T cells. [116] Raman 
spectroscopy has previously detected differences between T cells stimulated by αCD3/αCD28 
and alloantigen-activated T cells. [117] However, a comparison using biological indicators, such 
as IFN-γ production, revealed similar responses from T cells stimulated with either 
αCD3/αCD28 or an infectious agent. [118] Moreover, several other groups have stimulated T 
cell activation using αCD3/αCD28 for in vitro models of autoimmunity. [119, 120] We observed 
that unstimulated T cells had low levels of the activation marker, IL-2Rα, and its levels increased 
significantly following T cell stimulation. Thus, we believe our experimental setup is sufficient 
for modeling tolerance responses to different antigen delivery vehicles. 
NF-KB signaling in APCs can be triggered by ligand binding of Toll-like receptors (TLRs) 
on the cell surface resulting in an immune response. [121] Previous applications of the NF-KB 
inhibitor, BAY 11-7085, have shown reduced monocyte activation, as measured by lower levels 
of IL-1β and TNFα following co-culture with stimulated T cells or T cells isolated from 
rheumatoid arthritis. [122] When administered to dendritic cells, BAY 11-7085 attenuated 
maturation as measured by reduced expression of CD40, HLA-DR, CD83, and CD86 following 
exposure to haptens. [123] We found administering macrophages with antigen alongside BAY 
11-7085 resulted in increases of cytokine production, which may have differed from the reported 
monocyte behavior due to a cell-specific response. Administering antigen and BAY 11-7085 to 
dendritic cells did yield noticeable trends in T cell activity or cytokine production, possibly due 
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to the reduced impact of antigen presentation and co-stimulatory expression on T cells in the 
presence of αCD3/αCD28. 
The additional tolerance benefits from delivering antigen-coupled donor cells compared to 
antigen-coupled nanoparticles was evident in dendritic cells. Following SP-OVA treatment, 
dendritic cells brought about reduced T cell expression of IL-2Rα, increased T cell expression of 
L-selectin, increased T cell apoptosis, and reduced T cell proliferation. In addition, IFN-γ levels 
decreased while IL-10 levels remained high. These responses skewing towards tolerance are 
likely the result of triggering the same endogenous mechanisms used by dendritic cells to 
maintain peripheral tolerance to autoantigens found on apoptotic cells. [124] The mechanisms 
triggered by nanoparticle treatment, particularly in regard to inducing cytokine production are 
still unclear. [125] 
Although NF-KB inhibition was not sufficient to explain the additional tolerance effects 
induced by SP-OVA, network analysis of dendritic cells administered SP-OVA showed other 
transcription factors of interest. Specifically, CEBP was the most highly connected node, which 
suggests it is highly involved in implementing the tolerance effects resulting from SP-OVA 
treatment. Others have identified CEBP to be triggered in DCs following IL-10 and LPS 
treatment, leading to upregulation of chemokines, transduction molecules, and other transcription 
factors. [126] Further investigation of CEBP and its downstream effector molecules may 
generate additional targets for nanoparticle treatment to target in order to replicate the superior 
tolerance induction ability of donor cells. Antigen-coupled nanoparticles that can make 
additional use of endogenous tolerance pathways would provide a highly attractive platform to 









Chapter 6: Encapsulated CCR2-Targeting SiRNA Reduces Inflammatory Cell Migration and 
Disease Symptoms in Multiple Sclerosis Model 
6.1 Abstract 
The therapeutic potential of delivering small interfering RNA (siRNA) from nanoparticles 
to silence gene expression important for multiple sclerosis has yet to be explored. We 
encapsulated within biodegradable poly(lactide-co-glycolide) nanoparticles a mixture of siRNA 
complexed to polyethylenimine PLG(siCCR2-PEI) to target expression of the CCR2 chemokine 
receptor. Nanoparticles encapsulating fluorescent nucleic acids were observed to escape the 
endocytic internalization pathway, a necessary precursor for siRNA function. The activity of 
complexed and encapsulated siCCR2 was demonstrated by directly measuring CCR2 expression 
and evaluating cell migration toward CCL2. Induction of experimental autoimmune 
encephalomyelitis, a mouse model of multiple sclerosis was followed by 1.0 mg administrations 
of PLG(siCCR2-PEI) on Days 7, 9, and 11 post-induction, which significantly reduced mean 
clinical scores compared with administering either PLG encapsulating non-specific siRNA or 
buffered solution. These findings suggest PLG(siCCR2-PEI) may be useful for further 
development in the clinical treatment of multiple sclerosis and other autoimmune diseases. 
6.2 Introduction 
The therapeutic potential of RNA interference (RNAi) received tremendous interest and 
investment at the start of the 21st century. Some predicted RNAi would soon become a potent 
tool within the healthcare provider’s arsenal for treating a wide array of diseases. [127, 128] But 
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after many years of research and several clinical trials, a commercially available product has yet 
to emerge. Interestingly, several pharmaceutical companies have chosen instead to exit this 
research space. [129] While the difficulty of developing therapeutic RNAi may have initially 
been underestimated, advancements in nanoscale drug delivery systems offer potential solutions 
to overcome remaining challenges and enable RNAi to enter the clinic. 
Therapeutic RNAi strategies focus primarily on the use of small interfering RNA (siRNA). 
When introduced into the cell cytosol, these short, double-stranded RNA molecules associate 
with RNA-induced silencing complex (RISC) and possibly other factors to cleave and inhibit 
translation of mRNA molecules containing complementary sequence. [130] The activity of 
siRNA depends critically on its presence in the cytosol in order to associate with RISC and 
disrupt mRNA translation. A number of synthetic materials have been investigated as delivery 
vehicles to facilitate siRNA delivery to the cytosol. [131] 
Polymers are a versatile class of materials able to facilitate nucleic acid delivery into cells. 
Due to its negative charge, siRNA is often mixed with polycations, such as poly-L-lysine or 
polyethylenimine (PEI), resulting in self-assembly into more condensed structures, often called 
polyplexes. [132] The formation of polyplexes can improve the efficiency of siRNA 
encapsulation and subsequent release from poly(lactide-co-glycolide) (PLG) nanoparticles. [133] 
Several groups have previously used PLG nanoparticles to encapsulate siRNA for silencing 
TNFα expression and mitigating inflammation in both in vitro and in vivo models.[134, 135] 
These results demonstrate a possible role for siRNA to enhance or improve therapies currently 
used for autoimmune diseases. 
Multiple sclerosis is one of 81 identified autoimmune diseases and affects approximately 
58.3 per 100,000 people. [2] One of the most common treatments for multiple sclerosis is IFN-β, 
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which acts broadly and non-specifically to inhibit expression of MHC class II molecules, IL-12 
production, and T cell proliferation. [40] Unfortunately, patient complaints of flu-like symptoms 
or skin reactions have contributed to 5-year drop-out rates for IFN-β treatment that in certain 
studies are as high as 42%. [136] Alternative therapeutic interventions to incorporate siRNA 
which possesses a more specific mechanism of action may help to reduce the occurrence of side 
effects and improve patient compliance. 
Previous studies of immune components driving the pathogenesis of multiple sclerosis 
identified an important contribution of the CCL2/CCR2 chemokine signaling pathway. [137] 
Studies using experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple 
sclerosis, found that mice with genetic deletion of CCR2 had reduced cell infiltration in their 
central nervous systems and did not develop EAE pathology. [138] Expressed primarily on 
monocytes, CCR2 activation leads to extravasation and transmigration. Administering 
encapsulated siRNA to inhibit CCR2 expression has resulted in reductions of monocyte 
accumulation that were therapeutically beneficial in mouse models of atherosclerosis, 
myocardial infarction, pancreatic islet allograft, and cancer. [139] 
Herein we conducted several in vitro and in vivo studies to investigate the activity of 
siRNA designed specifically to inhibit CCR2 expression (siCCR2). Intracellular nanoparticle 
localization was first examined to verify their escape from the endocytic pathway into the cytosol 
to enable proper function. Subsequently, CCR2 expression was analyzed using direct 
measurement and also a cell migration assay following treatment of immune cells with siCCR2-
PEI polyplexes as well as with polyplexes encapsulated within PLG nanoparticles. Finally, we 




6.3 Materials and Methods 
6.3.1 Materials 
All siRNA was purchased from GE Dharmacon (Lafayette, CO) as mixtures containing 
four unique sequences. The siCCR2 mixture had the following sequences designed for specific 
silencing of mouse CCR2 expression: 5’CGAGUGAGCUCUACAUUCA3’, 
5’GGAGAGAAGUUCCGAAGGU3’, 5’CCAGGAAUCAUAUUUACUA3’, 
5’GUACUUGGCUAUUGUUCAU3’. The siCTRL mixture had the following sequences 
designed to each have at least 4 mismatches to all mouse, human, and rat genes: 
5’UAGCGACUAAACACAUCAA3’, 5’UAAGGCUAUGAAGAGAUAC3’, 
5’AUGUAUUGGCCUGUAUUAG3’, 5’AUGAACGUGAAUUGCUCAA3’. 
The following DNA oligonucleotide sequences were purchased from Integrated DNA 
Technologies (Coralville, IA): 5’/6-FAM/AGCTCAACATTCTGATAAGCTAC3’ and 
5’GAGTAGCTTATCAGAATGTTGAG3’. The PLP139-151 peptide was purchased from 
Genscript (Piscataway, NJ) and the MOG35-55 peptide was purchased from Celtek Peptides 
(Franklin, TN). Branched polyethylenimine (PEI), 25 kDa, and poly(vinyl alcohol), 30-70 kDa, 
were both purchased from Sigma-Aldrich (St. Louis, MO). Poly(lactide-co-glycolide) 50:50 
(PLG) with inherent viscosity of 0.2 dL/g was purchased from Lactel Absorbable Polymers 
(Birmingham, AL). 
6.3.2 Mice 
Female 6 to 12 week old C57BL/6 mice were purchased from Charles River Laboratories 
(Wilminton, MA). Female 6 to 12 week old SJL/J mice were purchased from Envigo 
(Indianapolis, IN). All experiments involving mice were approved by the University of Michigan 
Committee on the Use and Care of Animals. 
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6.3.3 Preparation of fluorescent nanoparticles 
PLG nanoparticles were synthesized using a single emulsion solvent evaporation technique 
as described previously. [92] Lyophilized nanoparticles were washed three times using 
phosphate-buffered solution (PBS) at pH 7.4. Approximately 4 mg of PLG nanoparticles was 
recovered and activated using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
purchased from Sigma-Aldrich (St. Louis, MO), at 16 mg/mL. Fluorescein cadaverine, 
purchased from Thermo Fisher Scientific (Waltham, MA) was immediately added to a final 
concentration of 4 μg/μL and the coupling reaction proceeded for 1 h under constant agitation. 
Uncoupled fluorophore was removed with three PBS washes. 
Complementary single-stranded DNA oligonucleotides containing a fluorophore molecule 
were combined at 40 μM in solution containing 5 mM NaCl, 1 mM Tris-HCl, 1 mM MgCl2, and 
0.1mM DTT. Sequences were heated at 95°C for 10 min before being cooled on ice for 10 min. 
The resulting double-stranded DNA was used within 24 h of annealing. PLG nanoparticles 
containing the annealed fluorescent DNA were formed in a similar process as the siRNA-
encapsulated nanoparticles described below. 
6.3.4 Fabrication of siRNA-encapsulated PLG nanoparticles 
Complexes of siRNA and PEI (siRNA-PEI) were first formed by mixing together at an N:P 
ratio of 8:1 and incubating at room temperature for 30 min. A 200 μL solution of the complexes, 
containing approximately 2 nmol of siRNA, was added to 0.5 mL of PLG dissolved in 
dichloromethane at 10% (w/v). A primary emulsion was formed by sonicating the solution with a 
Cole-Parmer CPX130 Ultrasonic Processor for 30 s. Subsequently, 2.5 mL of poly(vinyl alcohol) 
at 0.5% (w/v) was quickly added to the solution which was sonicated an additional 30 s to form 
the secondary emulsion. The emulsion was poured into 25 mL of poly(vinyl alcohol) at 0.5% 
80 
 
(w/v) and stirred overnight to evaporate the solvent. The resulting nanoparticles were washed 
three times and finally lyophilized in a solution of 4% (w/v) sucrose and 3% (w/v) D-mannitol.  
6.3.5 Nanoparticle characterization 
Nanoparticle size and ζ-potential were measured using a Zetasizer Nano ZSP from Malvern 
Instruments Ltd (Worcestershire, UK). To measure siRNA loading, nanoparticles were first 
dissolved for 30 min in dichloromethane. An equal volume of Tris-EDTA buffer was then added, 
vortexed for 1 min, and centrifuged at 12,000xg for 10 min. Nucleic acids in the aqueous phase 
were collected and quantified with the Quant-iT Picogreen dsDNA Assay Kit purchased from 
Thermo Fisher Scientific (Waltham, MA) using a standard curve built from siRNA-PEI. 
6.3.6 Intracellular localization of nanoparticles in vitro 
A primary population of macrophages was obtained as described previously. [90] Briefly, 
bone marrow was harvested from femurs and tibias of C57BL/6 mice and differentiated in vitro. 
Between 8 to 10 days following harvest, macrophages were collected and seeded at 
approximately 5.0 x 105 cells/mL in a Lab-Tek Chamber Slide System and activated with 
lipopolysaccharide (LPS) at 100 ng/mL. Fluorescent nanoparticles were reconstituted in water 
and added to chambers at 100 μg/mL. After 24 h of culture, cells were stained with LysoTracker 
Red DND-99 purchased from Thermo Fisher Scientific (Waltham, MA) according to the 
manufacturer’s instructions. Cells were fixed in 4% paraformaldehyde and cover slips were 
mounted on chamber slides with permount containing DAPI. Slides were imaged using either a 
Leica DM IRB fluorescent microscope or an Olympus FV 1200 confocal microscope. 
6.3.7 EAE initiation 
EAE disease was initiated as described previously. [85] Briefly, SJL/J and C57BL/6 mice 
were injected subcutaneously with emulsified PLP139-151 or MOG35-55, respectively, in complete 
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Freund’s adjuvant. C57BL/6 mice were also IP injected with 100 μL of pertussis toxin (2 ng/mL) 
purchased from Tocris Biosciences (Minneapolis, MN) on the same day and again 2 days later. 
For in vitro experiments, EAE-immunized mice were sacrificed 8 to 12 days after disease 
initiation, and blood within the heart was collected into Vacutainer tubes purchased from Becton, 
Dickinson and Company (Franklin Lakes, NJ). Red blood cells were lysed with ACK buffer 
manufactured by Life Technologies (Carlsbad, CA). 
For in vivo experiments, EAE-immunized mice were administered 1.0 mg of siRNA-
encapsulated PLG nanoparticles on days 7, 9, and 11 following disease initiation. Behavioral 
testing of mice was performed daily to determine clinical score, based on a 0-5 scale as follows: 
0, healthy; 1, limp tail; 2, limp tail and impaired righting reflex; 3, hind-limp weakness; 4, hind-
limb paralysis; and 5, moribund. 
6.3.8 Measuring function of siCCR2 in vitro 
To verify siRNA function, blood cells collected from EAE-immunized C57BL/6 mice were 
seeded into 24-well flat bottom plates at a density between 2.0 x 105 to 2.5 x 105 cells/mL using 
non-supplemented RPMI 1640 purchased from Life Technologies (Carlsbad, CA). Complexes of 
siCCR2 and PEI were added to cells at varying concentrations and analyzed 24 h later using flow 
cytometry. Cells were blocked in CD16/32, stained with αCCR2-Alexa Fluor 647 (clone 
SA203G11), and analyzed using a CyAn ADP Analyzer manufactured by Beckman Coulter 
(Brea, CA). Data was analyzed with FlowJo v10. Cellular events were gated using forward 
scatter and side scatter. FMO controls were used to identify cells with positive signal. 
CCR2 expression was investigated after treating cells with siRNA-encapsulated PLG 
nanoparticles. Blood cells were seeded as described above in 100 mm dishes. Nanoparticles were 
added at 100 μg/mL and CCR2 expression was measured 24 h later. Cell types were identified 
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using αLy6G-Brillian Violet 421 (clone 1A8), αLy6C-APC/Cy7 (clone HK1.4), and αCD45-
PerCP (clone 30-F11). 
6.3.9 Migration assays 
The migratory potential of treated cells was evaluated using Transwell cell culture inserts 
manufactured by Corning Incorporated (Oneonta, NY). Inserts were submerged in RPMI 1640 
containing 100 ng/mL of CCL2, a cytokine that binds CCR2 resulting in extravasation and 
transmigration, purchased from PeproTech (Rocky Hill, NJ). Blood cells collected from EAE-
immunized SJL/J mice or bone marrow-derived macrophages were seeded within inserts at 1.0 x 
106 cells/mL. After 24 h of treatment with either complexes or nanoparticles, migrated cells were 
dislodged from inserts using 5 mM EDTA and stained with calcein, AM, cell-permeant dye that 
was purchased from Thermo Fisher Scientific (Waltham, MA) according to the manufacturer’s 
instructions. Cell fluorescence was measured using a Synergy H1 Multi-Mode Reader 
manufactured by BioTek Instruments, Inc. (Winooski, VT) and correlated to known quantities of 
calcein-stained cells. 
6.4 Results 
6.4.1 Encapsulation of payload enables nanoparticle escape of endocytic pathway 
Nanoparticles containing surface-conjugated fluorophore (PLG-FITC) showed strong co-
localization with LysoTracker within bone marrow-derived macrophages following 24 h of 
nanoparticle treatment. (Fig 6.1a) The co-localization with LysoTracker, which stains acidic 
organelles such as lysosomes, suggested the retention of PLG-FITC within the endocytic 
pathway from cell internalization to lysosomal degradation. Interestingly, nanoparticles 
encapsulating short double-stranded DNA with an attached fluorophore [PLG(DNA-PEI)] were 
observed excluded from LysoTracker stains, suggesting escape of these nanoparticles from the 
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endocytic pathway and into the cytosol. (Fig 6.1b) The average diameter and zeta potential of 
PLG-FITC were 1146 nm and +29.9 mV, respectively, while the same measures for PLG(DNA-
PEI) were 480.3 nm and -16.4 mV. 
6.4.2 Bioactivity of complexed and encapsulated siCCR2 
Complex formation with PEI was verified using a fluorescent dye that emits signal when 
bound to double-stranded nucleic acids. Fluorescence intensity was linearly correlated with the 
concentration of double-stranded DNA both before and after complexation with PEI. (Fig 6.2) 
However, the fluorescent sensitivity of complexed DNA decreased dramatically, suggesting 
hindrance of fluorescent interaction between fluorescent dye and double-stranded nucleic acids 
due to the presence of PEI.  
Surface expression of CCR2 was measured on peripheral blood mononuclear cells 
(PBMCs) isolated from C57BL/6 mice 8 to 12 days following EAE induction. After 24 h of 
treatment with complexes of siCCR2 and PEI (siCCR2-PEI), a significant decrease of CCR2 
expression was observed among cells receiving 10 nM of siCCR2. (Fig 6.3a) This same dose of 
siCCR2-PEI was administered to PBMCs from SJL/J mice within a Transwell insert before 
placement inside a reservoir containing CCL2, the chemokine ligand for CCR2. The number of 
PBMCs migrating was similar to untreated PBMCs placed inside a reservoir without CCL2, both 
of which were significantly lower than the migration of PBMCs not receiving siCCR2-PEI and 
placed inside a CCL2-containing reservoir. (Fig 6.3b) These results indicate the ability of 




Figure 6.1 Intracellular nanoparticle localization within bone marrow-derived 
macrophages. MΦs were cultured on chamber slides for 24 h with (a) 10 μg/mL of PLG-FITC 
(green) and imaged using a Leica DM IRB fluorescent microscope or (b) 50 μg/mL of 
PLG(DNA-PEI) (green) and imaged using an Olympus FV 1200 Confocal Microscope. White 
arrows indicate observations of green fluorescent signal excluded from red fluorescent signal. 
Cells were stained with lysotracker (red) and slides were mounted with coverslips using 





Figure 6.2 Formation of siRNA-PEI polyplexes. The Quant-iT PicoGreen dsDNA Assay Kit 
was highly sensitive to annealed DNA oligonucleotides (dsDNA) as shown by a steep best-fit 
line with coefficient of determination equal to 0.986. Mixture of the dsDNA with PEI (dsDNA-
PEI) resulted in a dramatic reduction of sensitivity suggesting polyplex formation as shown by a 





Figure 6.3 Direct measurement and functional detection of siCCR2-PEI activity in vitro. (a) 
PBMCs isolated from EAE-immunized mice were cultured with increasing concentrations of 
siCCR2-PEI for 24 h before CCR2 surface expression analysis using flow cytometry. The mean 
fluorescence intensity of CCR2 expression significantly decreased on PBMCs treated 10 nM of 
siCCR2-PEI. (b) The number of PBMCs migrating into a Transwell membrane significantly 
increased in the presence of 100 ng/mL CCL2. The additional migration in response to CCL2 
was no longer observed when PBMCs were treated with 10 nM of siCCR2-PEI. Data show 
averages of three measurements ± standard error of mean (SEM). (*p < 0.05, **p < 0.01, 1-way 





6.4.3 Bioactivity of encapsulated siCCR2-PEI 
The physicochemical properties of PLG nanoparticles were measured following 
encapsulation of siCCR2-PEI. The average diameter was 448.6 nm and the average zeta potential 
was -16.5 mV. Encapsulation efficiency was approximately 7.7%, resulting in total siCCR2 
loading of approximately 30.9 pmol per mg of PLG. Blank PLG nanoparticles synthesized in 
parallel without the encapsulation of siCCR2-PEI had average diameter of 381.9 nm and average 
zeta potential of -22.6 mV. 
Blank nanoparticles (PLG) or nanoparticles containing siRNA complexes [PLG(siCCR2-
PEI)] were both administered to PBMCs isolated from SJL/J mice 10 days after EAE induction. 
After 24 h of nanoparticle treatment, reduced surface expression of CCR2 was measured among 
PBMCs administered PLG(siCCR2-PEI) compared to PLG. (Fig 6.4) This reduction was 
observed in both Ly6G+ PBMCs and Ly6C+ PBMCs, cell identification markers which are 
typically associated with neutrophils and monocytes. 
To control for differences occurring simply due to siRNA treatment, PLG nanoparticles 
encapsulating complexes of control siRNA lacking any sequence complementarity within the 
mouse genome [PLG(siCTRL-PEI)] were administered to bone marrow-derived macrophages 
alongside PLG(siCCR2-PEI). Both formulations were able to reduce CCR2 expression (Fig 








Figure 6.4 Direct measurement of encapsulated siCCR2-PEI activity in vitro. PBMCs 
isolated from EAE-immunized mice were administered either blank nanoparticles (PLG) or 
nanoparticles containing siCCR2 polyplexes [PLG(siCCR2-PEI)] for 24 h before CCR2 surface 
expression analysis by flow cytometry. (a) The mean fluorescence intensity of CCR2 expression 
among Ly6G+ PBMCs decreased from 356 to 90 between treating cells with PLG and 
PLG(siCCR2-PEI). (b) The mean fluorescence intensity of CCR2 expressing among Ly6C+ 






Figure 6.5 Direct measurement and functional detection of encapsulated siCCR2-PEI 
activity in vitro. (a) Bone marrow-derived macrophages were administered nanoparticles 
encapsulating either control siRNA polyplexes [PLG(siCTRL-PEI)] or siCCR2 polyplexes 
[PLG(siCCR2-PEI)] for 24 h before CCR2 surface expression analysis by flow cytometry. The 
mean fluorescence intensity of CCR2 expression among macrophages significantly decreased in 
response to PLG(siCTRL-PEI) and to a greater extent in response to PLG(siCCR2-PEI) 
compared to macrophages receiving no treatment. (b) The number of macrophages migrating 
into Transwell membranes in the presence of 100 ng/mL of CCL2. Treating macrophages with 
PLG(siCCR2-PEI) for 24 h prior to Transwell culture resulted in a significant decrease of 
migration compared to macrophages receiving no treatment. To a lesser extent, treatment with 
PLG(siCTRL-PEI) also significantly reduced migration compared to macrophages receiving no 
treatment. Data show averages of three measurements ± standard error of mean (SEM). (**p < 




6.4.4 Encapsulated siCCR2 abrogates EAE disease severity 
A 1.0 mg dose of nanoparticles encapsulating siRNA was intravenously administered every 
other day for a total of three injections following EAE induction in C57BL/6 mice. EAE disease 
course proceeded similarly in all treatment groups for several days following the final injection. 
(Fig 6.6) At around Day 16, mice receiving PLG(siCTRL-PEI) began to show accelerated 
disease progression compared to mice receiving either PBS or PLG(siCCR2-PEI) which had 
more similar prognoses. However, beyond Day 30, disease progression in the PLG(siCTRL-PEI) 
and PBS groups had become indistinguishable, while significantly lower clinical score was 
observed in the PLG(siCCR2-PEI) group. These observations suggest treatment with 
PLG(siCCR2-PEI) provided immunosuppressive effects during a critical stage of disease 





Figure 6.6 EAE disease course following multiple injections of nanoparticles encapsulating 
siRNA polyplexes. C57BL/6 mice received 1.0 mg injections of the appropriate nanoparticle 
treatment or phosphate buffer solution (PBS) on days 7, 9, and 11 following induction of EAE 
disease as indicated by the arrows. In the days following treatment, mice receiving 
PLG(siCTRL-PEI) had more rapid escalation of disease symptoms compared to the other 
treatment groups. In later stages of disease, the PBS-treated group also displayed severe EAE 
symptoms similar to mice receiving PLG(siCTRL-PEI), however, the condition of mice 
receiving PLG(siCCR2-PEI) stabilized with moderate disease symptoms. Data show averages of 
four to five mice with error bars omitted for clarity. (**p < 0.01, ****p < 0.0001, 1-way 





Delivering siRNA molecules to the cytosol is critical for their proper function, and the 
location of their intracellular accumulation following administration is strongly influenced by 
physicochemical properties of the nanoparticles. After PLG nanoparticles are internalized, they 
are transported along the endocytic pathway, which becomes increasingly acidic in transit to the 
lysosome, which has an approximate pH of 4.5-5.0. [13] The decrease of pH causes the zeta 
potential of PLG to increase, such that an initial -15 mV at physiological pH (7.0) can become 
+2.5 mV at acidic pH (4.0). [140] This transition of zeta potential from negative to positive may 
disrupt the compartmental membrane entrapping the nanoparticles, allowing the compartmental 
contents which include the PLG nanoparticles to escape into the cytosol. 
Despite the low encapsulation efficiency of siCCR2 molecules, we detected their activity 
both via direct measurement and indirect functional assays of CCR2 following nanoparticle 
treatment. Previous reports of delivering siRNA from PLGA nanoparticles found that treating 
cells with nanoparticles equivalent to 5 pmol of siRNA was sufficient for 80-90% knock-down 
of luciferase gene expression. [141] Our in vitro studies used nanoparticle concentrations of 100 
μg/mL, which based on a total siRNA loading of 30.9 pmol per mg of PLG, is on the same order 
as 5 pmol of siRNA. Thus, the amount of siCCR2 administered in vitro was in good agreement 
with the amount others have reported using to achieve detectable siRNA activity.  
The in vivo effects of encapsulated siCCR2 suggest a moderate therapeutic potential that 
may be further improved by adjusting their administration frequencies or dosage. The days on 
which nanoparticles were administered was determined based on previous dosing regimens. 
Specifically, it was reported that daily administration of 0.355 mg of blank PLG nanoparticles 
starting 7 days post EAE induction was effective to reduce disease severity during the acute 
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phase of relapse-remitting EAE. [142] Moreover, when nanoparticle administration was 
discontinued, the effect of the nanoparticles slowly faded such that EAE severity eventually 
became indistinguishable with the group not receiving nanoparticle treatment. Interestingly, we 
detected a persistent effect of nanoparticle treatment. One explanation for these differences may 
be due to our use of a chronic-progressive EAE model rather than the relapse-remitting EAE 
model. Morphological studies of the chronic-progressive model have shown simultaneous 
inflammation in the brain, spinal cord, and cerebellum while the relapse-remitting model may be 
characterized by waves of inflammation to the various organs of the central nervous system. 
[143]  
Therefore we hypothesize inflammation in the chronic-progressive model is focused in the 
initial days of disease which were more effectively curtailed by the short course of nanoparticle 
treatment which reduced the occurrence of irreversible neuronal damage which occurs over a 
longer period of time in the relapse-remitting model. This hypothesis could be further supported 
by studies investigating when in the disease course neuronal damage becomes irreparable. 
Using siRNA to stimulate the immune system may create additional therapeutic benefits for the 
specific case of treating multiple sclerosis. The standard treatment of multiple sclerosis currently 
involves repeated injections of IFN-β which results in skin reactions at the injection site that can 
be severe enough to cause termination of treatment. [144] Several cell types within the immune 
system express Toll-like receptors (TLRs), specifically TLR3 and TLR7, which recognize 
double-stranded and single-stranded RNA, respectively. Activation of these TLRs would initiate 
signaling cascades that increase production of IFN-β. [145] While the siRNA used in this study 
contained the 2’-O-methyl modification which reduces immune stimulation, sequence design can 
be optimized to potentially trigger TLR activation. [146, 147] Using siRNA to induce 
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endogenous production of IFN-β may provide therapeutic effects for treating multiple sclerosis 









Chapter 7: Conclusions and Future Directions 
 The research investigations described in the preceding chapters examined the mechanism 
of action used by a nanoparticle-based approach to deliver antigen-specific therapy in the 
treatment of autoimmune diseases. A direct mechanistic comparison was made between antigen 
delivery using the nanoparticle-based approach and a cell-based approach also effective for 
inducing antigen-specific tolerance. Considering instances in which antigen-specific tolerance is 
not possible or desirable, RNA interference was incorporated within the nanoparticle design to 
suppress the activity of specific immune signaling pathways correlated with autoimmune 
pathology. Herein, we discuss the major research findings and their potential implications for the 
drug delivery research field and development of more targeted autoimmune therapies. 
7.1 Peptide-Conjugated Nanoparticles Reduce Positive Co-Stimulatory Expression and T Cell 
Activity to Induce Tolerance 
7.1.1 Conclusions 
Identifying cells with MHC-restricted antigen on the surface, and conducting analysis on 
this subpopulation of cells was a major novel component to this study. Previous mechanistic 
analyses of nanoparticle-mediated antigen delivery primarily examined co-stimulatory 
expression on entire populations of antigen-presenting cells (APCs). [148] Depending on the 
efficiency of antigen delivery and processing, such analysis may include a large number of cells 
unable to interact with T cells and affect the adaptive immune response. Our studies showed that 
nanoparticles with the highest amount of antigen coupling, administered at the highest dosage, 
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resulted in only about 25% of APCs with detectable levels of surface MHC-restricted antigen. 
The ability for APCs to signal T cells depends on engaging the T cell receptor using MHC-
restricted antigen. In the absence of this interaction, levels of co-stimulatory expression on the 
APC are likely to be inconsequential. Thus, future studies of exogenous antigen delivery may 
benefit from incorporating strategies to focus analysis on cells expressing detectable levels of 
MHC-restricted antigen. 
APCs had low efficiency of antigen presentation despite a high percentage of 
nanoparticle internalization. It may be useful to generate APC populations with 0%, 25%, 50% 
and 100% of cells expressing MHC-restricted antigen, and examine the response of T cells in co-
culture. Perhaps not all APCs within the population need to present antigen in order to impact T 
cell response. It would be interesting to determine if the marginal increase of T cell response 
reaches a plateau once a certain threshold percentage of APCs expressing MHC-restricted 
antigen is reached in co-culture with a 2:1 T cell to APC ratio. Previous studies administering a 
high dose of toxin to APCs reported a positive correlation between the number of APCs and the 
amount of T cell proliferation which did not reach a plateau even as the T cell to APC ratio 
decreased from 1000:1 to 1:1, [149] suggesting that availability of MHC-restricted antigen for 
engaging T cell receptors is typically the limiting factor. 
 To achieve higher percentages of APCs expressing MHC-restricted antigen, the linker 
strength connecting antigen and nanoparticle could be further modulated. Reducing the linker 
strength could liberate additional antigen to bind MHC class II molecules during endocytic 
transit following nanoparticle internalization.  In fact, one hypothesis for the low efficiency of 
antigen presentation despite the high efficiency of nanoparticle internalization is that antigen 
remains attached to the nanoparticle which prevents its loading onto MHC molecules. Rather the 
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antigen is retained in the endocytic pathway until reaching the lysosome for degradation. A 
reduced linker strength may be similar to the burst release phenomenon, which describes the 
release of a large percentage of encapsulated payload during the initial timeframe following 
nanoparticle reconstitution into solution. Studies of antigen-encapsulated nanoparticles with 
varying propensities for burst release found that nanoparticles with low burst release were more 
efficient for activating CD8+ T cells compared to nanoparticles with high burst release. [150] 
Assuming burst release is an adequate approximation for linker strength, these results would then 
conflict with the aforementioned hypothesis. However, there are considerable differences in the 
processes of antigen loading onto MHC class I molecules to signal CD8+ T cells compared to 
antigen loading onto MHC class II molecules to signal CD4+ T cells, and thus a similar study is 
needed using antigen containing MHC class II epitopes with CD4+ T cells. 
 The in vitro assays involving autoreactive T cells co-cultured with nanoparticle-treated 
APCs might generate a more clear readout if the T cells receive further purification prior to co-
culture. The percentage of T cells in lymphoid organs specific to one particular antigen is 
initially very low. A moderate increase occurs when an immune response is induced against the 
antigen, or instead obtaining T cells from mice with transgenic T cell receptors. However, even 
following successive rounds of antigen stimulation in vitro, the percentage of antigen-specific T 
cells from either source does not exceed 50%. [151] Further enrichment for antigen-specific T 
cells may improve the readout of the antigen-specific response by removing T cells lacking 
specificity to the antigen. Various techniques exist to purify antigen-specific cells, although the 
yield and purity vary dramatically. [152] Raman spectroscopy has demonstrated the ability to 
distinguish subtle differences among T cells activated by different stimuli. [117] In the years 
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ahead, Raman spectroscopy may become a critical tool similar to flow cytometry for cell 
analysis and sorting, but via a label-free approach. [153] 
7.1.2 Future Directions 
This investigation assembled a useful set of in vitro assays to probe the mechanisms that 
may be involved in the induction of antigen-specific tolerance in vivo. These assays could be 
further assembled into an initial screening approach to explore novel nanoparticle formulations. 
Nanoparticles can vary in size, shape, and charge due to the fabrication process, not to mention 
different materials, solvents, and surface coatings. Certain combinations of these 
physicochemical properties and compositions may offer improved tolerance induction compared 
to the combinations previously explored and currently used. Testing all of these combinations in 
vivo would be infeasible, however, some of the in vitro assays developed here may be useful for 
early discovery of promising combinations for further investigation. 
The number of peptide antigens with an antibody able to detect antigen loading on MHC 
molecules needs to be dramatically increased. Currently, the available antibodies to detect MHC-
restricted antigen presentation are limited to detecting model antigens that have minimal disease 
relevance. Measuring levels of antigen presentation for disease-relevant antigens would improve 
data quality, especially as nanoparticles are used in vivo. The availability of an antibody library 
to target various disease-relevant antigens when loaded onto MHC molecules would be a major 
benefit to mechanistic studies of antigen-specific autoimmune therapies.  
The ability to measure levels of MHC-restricted disease-relevant antigens would serve as 
biomarkers of nanoparticle therapeutic activity. Following nanoparticle administration, a tissue 
biopsy from the inflammatory site could be purified for APCs and subsequently analyzed for 
antigen presentation levels. Measuring the amount of antigen presentation and co-stimulatory 
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expression occurring in sites of inflammation, such as the central nervous system in multiple 
sclerosis, would be useful for fine-tuning nanoparticle dose and monitoring nanoparticle activity 
over time. Moreover, these antibodies may have future therapeutic applications as their 
attachment to disease-relevant antigen loaded onto MHC molecules may specifically disrupt the 
ability to activate self-reactive T cells. 
7.2 The Role of NF-KB Signaling Due to Antigen-Coupled Nanoparticles or Cells Administered 
for Antigen-Specific T Cell Tolerance 
7.2.1 Conclusions 
In the presence of αCD3/αCD28, T cells co-cultured with dendritic cells administered 
antigen-coupled donor cells (SP-OVA) had significant reductions of several activation indicators 
compared to administering antigen-coupled nanoparticle (PLG-OVA) or soluble antigen (OVA). 
SP-OVA also reduced levels of pro-inflammatory cytokine (IFNγ) while maintaining levels of 
anti-inflammatory cytokine (IL-10). Together, these measurements reveal a superior capability 
for SP-OVA to induce tolerance compared to PLG-OVA or OVA. 
A small molecule inhibitor (BAY 11-7085) of the transcription factor NF-KB was also 
administered in conjunction with antigen. If the improved tolerance effects of SP-OVA had 
occurred via increased NF-KB signaling, the presence of BAY 11-7085 would have in effect 
negated SP-OVA treatment resulting in T cell measurements more similar to other treatment 
groups. Conversely, if SP-OVA induced tolerance via decreased NF-KB signaling, the presence 
of BAY 11-7085 should have conferred the same advantages to OVA and PLG-OVA. However, 
there was minimal correlation detected when dendritic cells were administered BAY 11-7085 
alongside the different antigen delivery vehicles, suggesting a limited role of NF-KB in the 
mechanism of tolerance resulting from SP-OVA treatment of dendritic cells. Interestingly, the T 
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cell response changed dramatically following macrophage treatment with BAY 11-7085 
regardless of OVA, PLG-OVA, SP-OVA, suggesting an important role of NF-KB signaling in 
macrophages, which was confirmed by network analysis of TRanscriptional Activity CEll aRray 
(TRACER) studies. Network analysis of transcriptional activity in treated macrophages inferred 
NF-KB as a central hub within the signaling network. Due to its location within the network and 
based on the observed co-culture responses, we conclude NF-KB plays a critical role in 
macrophage signaling. This is a similar approach used by others to draw conclusions following 
network analysis of macrophage transcriptional regulation to focus on the importance of the 
central hubs. [154] 
The TRACER network analysis suggested that other signaling molecules, such as those 
from the CEBP (CCAAT-enhancer-binding protein) family may be more involved than NF-KB 
to affect the cell response following SP-OVA treatment of dendritic cells. One important caveat 
is that the TRACER studies only examined 14 transcription factors, and there are upwards of 
1,000 transcription factors in the human genome. [25] The 14 factors evaluated here were 
selected for their relevance to immune signaling pathways, but it is highly plausible that other 
signaling molecules not included in this study were triggered by SP-OVA and are important in 
the subsequent tolerance induction. Additional methods to provide higher analytical throughput 
may help to further elucidate the mechanism at work. These methods would include microarrays 
and CyTOF, both of which have been previously used to efficiently investigate transcriptional 
regulation. [155, 156] 
7.2.2 Future Directions 
The screening of additional small molecule inhibitors to target alternate signaling 
pathways may also help to elucidate additional unique tolerance mechanisms triggered by SP-
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OVA and not PLG-OVA. Studies of an autoimmune response enhanced by IL-18 treatment 
detected therapeutic benefits from administering an inhibitor of PI 3-kinase. [122] Other small 
molecule inhibitors investigated included a MAPK p38 inhibitor, ERK inhibitor, and JNK 
inhibitor, although they did not reverse the immune response triggered by IL-18. Applying these 
inhibitors in the same way that BAY 11-7085 was administered to APCs alongside antigen 
delivery may reveal the involvement of additional signaling molecules in the tolerance 
mechanism. 
TRACER analysis measured the activity and interactions of 14 transcription factors, 
however improvements to scale up TRACER are necessary to more completely profile the cell 
signaling response to different treatments. Currently, cells are seeded into wells, and each well 
receives only one specific reporter. The ability to add additional reporters to the same well would 
dramatically reduce the size and complexity of a TRACER experiment. This would be possible if 
reporters emit signal at different wavelengths that a detection instrument could discriminate, 
similar to the technique of multi-parameter flow cytometry.  
However, a more stringent limit for combining TRACER reporters is needed relative to 
flow cytometry. In flow cytometry, the measured signal is introduced to cells through the various 
fluorescently-coupled antibodies, and the maximum number of antibodies to apply to a cell is 
limited by the ability to discriminate the combined signals. In TRACER and other dynamic 
measurement techniques, measured signal is synthesized by the cell under analysis, and the 
maximum number of transcription factors to analyze in a cell is limited by toxicity issues from 
intracellular accumulation of reporter molecules. 
Additional experimental tools to dynamically detect transcription factor activity would 
improve TRACER analysis. These improvements would be to develop transgenic immune cells 
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with fluorescently-labeled transcription factors. There currently exist only a small number of 
transgenic mouse lines with fluorescently-labeled gene expression in hematopoietic cells, with a 
select few of these labeled genes being transcription factors. [157] Increasing the available 
number of transgenic fluorescently-labeled transcription factors would allow TRACER 
experiments to be run both in vitro and in vivo with greater ease. These transgenic mice would 
also reduce the expense and biosafety concerns of producing viral vectors, as well as the batch-
to-batch variability of stable genomic integration following viral transduction. Further 
improvements of this transgenic approach would modify fluorescent labeling of transcription 
factors to be conditional with nuclear translocation in order to focus fluorescent measurement on 
transcription factors actively mediating gene expression. 
7.3 Encapsulated CCR2-Targeting SiRNA Reduces Inflammatory Cell Migration and Disease 
Symptoms in Multiple Sclerosis Model 
7.3.1 Conclusions 
 A major question resulting from this work is whether substantive additional amounts of 
siRNA can be further encapsulated into PLG nanoparticles. The total loading achieved here was 
comparable with previous reports using a similar molecular weight (5 kDa) of PLG but in the 
absence of PEI. [133] This study further showed that increasing to a higher molecular weight of 
PLG (40 kDa) with PEI resulted in twice the total siRNA loading. Using poly(lactide) 
nanoparticles, others have shown increasing the N:P ratio from the 8:1 used here to 16:1 results 
in a marginal increase of siRNA loading. While the amount of siRNA delivered was sufficient to 
induce a detectable response both in vitro and in vivo, it would be useful to examine possible 
improvements in efficacy or duration of siRNA activity due to additional loading. However, 
increasing polymer molecular weight is anticipated to prolong degradation time and 
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incorporating additional cationic polymer may create harmful aggregations with serum proteins, 
both of which would contribute to increased toxicity. [158] It was routinely observed in vitro that 
nanoparticle concentrations above 100 μg/mL as well as siRNA-PEI concentrations above 50 nM 
resulted in large reductions of cell viability. 
Modifying the nanoparticle surface charge may reveal additional formulations to provide 
greater accumulation of siRNA in the cytosol. The accumulation of free siRNA in the cytosol is 
critical for its ability to function. Nanoparticle encapsulation assists with delivering siRNA to the 
intended tissues and cells, but siRNA must then exit the endocytic pathway, shed the 
nanoparticle, and disentangle from PEI to ensure proper siRNA activity. There is still much 
debate within the field regarding the intracellular mechanisms governing siRNA accumulation in 
the cytosol and the potential impacts of polymer-mediated buffering and changes to pH. [159] 
However, we can expect additional coatings or layers to the nanoparticle will improve their 
circulation time in the blood to increase targeting of inflammatory cells that contribute to 
autoimmunity. [160] In lieu of basic principles governing nanoparticle escape of the endocytic 
pathway and accumulation in the cytosol, empirical testing may be necessary to determine the 
most optimal formulation to address each therapeutic context. 
7.3.2 Future Directions 
Extending the work initiated here would involve combining siRNA delivery with antigen 
delivery to induce more durable, long-lasting antigen-specific immune tolerance. Based on the 
mechanistic studies examining intracellular and intercellular signaling, more effective tolerance 
induction may occur when antigen is delivered alongside siRNA molecules targeted against 
transcription factors, such as NF-KB and AP-1, or cytokines, such as IFN-γ and IL-2. One 
approach for co-delivery of antigen and siRNA would be to encapsulate siRNA molecules into 
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antigen-coupled nanoparticles to potentially further enhance their antigen-specific tolerance 
effects. But multi-functional nanoparticles may be difficult to generate with high loading of all 
payloads while maintaining good control over physicochemical properties. Therefore designing 
modular nanoparticles may be more feasible to develop further.  
Modular nanoparticles for induction of immune tolerance could be synthesized to contain 
either antigen or siRNA only. Separating the two payloads may improve the targeting of each to 
the different intracellular locations necessary for each molecule’s bioactivity. Antigen with class 
II epitopes must encounter MHC-II molecules in the endocytic pathway in order to be presented 
on the cell surface. In contrast, siRNA must enter the cytosol to associate with RISC in order to 
degrade mRNA transcripts. These final destinations are largely incompatible, as retention in the 
endocytic pathway to benefit antigen presentation would reduce siRNA accumulation in the 
cytosol, and vice versa. Thus separating these two payloads into different nanoparticles would 
allow physicochemical properties to be separately tuned to facilitate accumulation within the 
desired intracellular regions. 
Modular nanoparticles would also provide greater flexibility in clinical settings that may 
favor the use of either antigen or siRNA only for treatment. In certain cases of autoimmunity 
where the risk of anaphylaxis is high or epitope spreading has already occurred, the 
administration of antigen may not be desirable or effective. In these cases, delivery of 
nanoparticles carrying siRNA only would be a more effective therapeutic option. But if the 
autoantigen is well-characterized and serum autoantibody levels have been determined as low, 
then it may be advantageous to co-deliver nanoparticles carrying antigen and siRNA to induce 
robust immune tolerance. This approach of developing modular nanoparticles that can be mixed 
together and administered as a cocktail therapy represent tailored therapeutic approaches for 
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specific patient needs, in line with precision medicine which will help to advance cutting-edge 
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